WO2022179469A1 - 噻吩并嘧啶二酮类化合物及其应用 - Google Patents
噻吩并嘧啶二酮类化合物及其应用 Download PDFInfo
- Publication number
- WO2022179469A1 WO2022179469A1 PCT/CN2022/077035 CN2022077035W WO2022179469A1 WO 2022179469 A1 WO2022179469 A1 WO 2022179469A1 CN 2022077035 W CN2022077035 W CN 2022077035W WO 2022179469 A1 WO2022179469 A1 WO 2022179469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- added
- mmol
- acceptable salt
- Prior art date
Links
- QAFVXBQPQCSSLI-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)NC2=C1SC=C2 QAFVXBQPQCSSLI-UHFFFAOYSA-N 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 118
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 102000008238 LHRH Receptors Human genes 0.000 claims description 16
- 108010021290 LHRH Receptors Proteins 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 229940044551 receptor antagonist Drugs 0.000 claims description 10
- 239000002464 receptor antagonist Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 150000001924 cycloalkanes Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 234
- 239000000243 solution Substances 0.000 description 139
- 238000006243 chemical reaction Methods 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 101
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- 239000012074 organic phase Substances 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 61
- 239000000203 mixture Substances 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000000706 filtrate Substances 0.000 description 42
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- 238000005481 NMR spectroscopy Methods 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- -1 dose volume Substances 0.000 description 29
- 239000003208 petroleum Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 239000012267 brine Substances 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 239000012043 crude product Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 239000012065 filter cake Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000004237 preparative chromatography Methods 0.000 description 8
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 101000996727 Homo sapiens Gonadotropin-releasing hormone receptor Proteins 0.000 description 5
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 5
- 102000057996 human GNRHR Human genes 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 5
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- BVPIEXVRGAEGBO-UHFFFAOYSA-N 3-(chloromethyl)-1,2-difluoro-4-methoxybenzene Chemical compound COC1=CC=C(F)C(F)=C1CCl BVPIEXVRGAEGBO-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 201000009273 Endometriosis Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- SXGBREZGMJVYRL-UHFFFAOYSA-N butan-1-amine;hydrobromide Chemical compound [Br-].CCCC[NH3+] SXGBREZGMJVYRL-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 2
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 2
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 2
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- LVHOHZHTZXRVRJ-CMDGGOBGSA-N (e)-3-(3-methoxyphenyl)-n-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC=2C=C(OC)C(OC)=C(OC)C=2)=C1 LVHOHZHTZXRVRJ-CMDGGOBGSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NMPVEAUIHMEAQP-UHFFFAOYSA-N 2-Bromoacetaldehyde Chemical compound BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 2
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 2
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 2
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 2
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- PPJKLEQAFZWIQY-UHFFFAOYSA-N 5-fluoro-2-methoxyphenol Chemical compound COC1=CC=C(F)C=C1O PPJKLEQAFZWIQY-UHFFFAOYSA-N 0.000 description 2
- HCFZUTSDEMKXQB-UHFFFAOYSA-N 6-[2-[2-(4-bromophenoxy)propan-2-yl]-4-pyridin-3-yl-1,3-dioxan-5-yl]hex-4-enoic acid Chemical compound O1CC(CC=CCCC(O)=O)C(C=2C=NC=CC=2)OC1C(C)(C)OC1=CC=C(Br)C=C1 HCFZUTSDEMKXQB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- UFMQJYHLIUACCG-UHFFFAOYSA-N 8-nitroindolo[2,1-b]quinazoline-6,12-dione Chemical compound C1=CC=C2C(=O)N3C4=CC=C([N+](=O)[O-])C=C4C(=O)C3=NC2=C1 UFMQJYHLIUACCG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 2
- 229940126559 Compound 4e Drugs 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125872 compound 4d Drugs 0.000 description 2
- 229940126115 compound 4f Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940127108 compound 5g Drugs 0.000 description 2
- 229940126136 compound 5i Drugs 0.000 description 2
- 229940125801 compound 7f Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- YWKVMGDEOUPQGN-UHFFFAOYSA-N ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C#CC1(O)C(CC2)CCN2C1 YWKVMGDEOUPQGN-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 2
- KQNYTTDHCMFOME-UHFFFAOYSA-N methyl n-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-n-phenylcarbamate Chemical compound C=1C=CC=CC=1N(C(=O)OC)NC(=O)C(C1=CC=CC(F)=C1N=C1C=2C=CC=CC=2)=C1CN1CCN(C(C)(C)C)CC1 KQNYTTDHCMFOME-UHFFFAOYSA-N 0.000 description 2
- PHHRKRGXWSEXFZ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-3-[[2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzoxazol-4-yl]oxy]propan-1-amine Chemical compound FC1=C(F)C(F)=CC=C1OCC(OC1=CC=C2)=NC1=C2OCCCNCC1=CC=CN=C1 PHHRKRGXWSEXFZ-UHFFFAOYSA-N 0.000 description 2
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 2
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 2
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 2
- VQVCFYIDCWPSNE-UHFFFAOYSA-N n-methyl-3-[(2-naphthalen-2-ylacetyl)amino]benzamide Chemical compound CNC(=O)C1=CC=CC(NC(=O)CC=2C=C3C=CC=CC3=CC=2)=C1 VQVCFYIDCWPSNE-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- DMQYDVBIPXAAJA-VHXPQNKSSA-N (3z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1h-imidazol-2-yl)methylidene]-1h-indol-2-one Chemical compound C1CN(CC)CCC1NC1=CC=C(NC(=O)\C2=C(/C=3NC=C(C)N=3)C=3C=C(F)C=CC=3)C2=C1 DMQYDVBIPXAAJA-VHXPQNKSSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- DSEVNUCNUTYYHW-UHFFFAOYSA-N 1,2-difluoro-4-methoxybenzene Chemical compound COC1=CC=C(F)C(F)=C1 DSEVNUCNUTYYHW-UHFFFAOYSA-N 0.000 description 1
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 description 1
- HCXZOHFGXHDGRF-UHFFFAOYSA-N 2,3-difluoro-6-hydroxybenzaldehyde Chemical compound OC1=CC=C(F)C(F)=C1C=O HCXZOHFGXHDGRF-UHFFFAOYSA-N 0.000 description 1
- SMRYCTJAGPDVEH-UHFFFAOYSA-N 2,4-difluoro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=C(F)C=C1F SMRYCTJAGPDVEH-UHFFFAOYSA-N 0.000 description 1
- KKKJYDOHVKIIQP-UHFFFAOYSA-N 2-[4-(3-chlorobenzoyl)phenoxy]-N-pyridin-3-ylacetamide Chemical compound ClC=1C=C(C(=O)C2=CC=C(OCC(=O)NC=3C=NC=CC=3)C=C2)C=CC=1 KKKJYDOHVKIIQP-UHFFFAOYSA-N 0.000 description 1
- NVNFKCCUJKPLLT-UHFFFAOYSA-N 2-bromo-4-fluoro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=C(F)C=C1Br NVNFKCCUJKPLLT-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BMAAMIIYNNPHAB-UHFFFAOYSA-N 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1h-thieno[3,4-d]pyrimidine-5-carboxylic acid Chemical compound COC1=CC(F)=C(N2C(C3=C(C(O)=O)SC=C3NC2=O)=O)C=C1OCC1=C(OC)C=CC(F)=C1F BMAAMIIYNNPHAB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OULGLTLTWBZBLO-UHFFFAOYSA-N 4-fluoro-2-methoxyphenol Chemical compound COC1=CC(F)=CC=C1O OULGLTLTWBZBLO-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- PJGJQVRXEUVAFT-UHFFFAOYSA-N chloroiodomethane Chemical compound ClCI PJGJQVRXEUVAFT-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- NSSMTQDEWVTEKN-UHFFFAOYSA-N diethoxy(methyl)phosphane Chemical compound CCOP(C)OCC NSSMTQDEWVTEKN-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- LDCRTTXIJACKKU-ARJAWSKDSA-N dimethyl maleate Chemical compound COC(=O)\C=C/C(=O)OC LDCRTTXIJACKKU-ARJAWSKDSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- DXPIZCZNFUTPEI-UHFFFAOYSA-O diphenylphosphanium;azide Chemical compound [N-]=[N+]=[N-].C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 DXPIZCZNFUTPEI-UHFFFAOYSA-O 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229950004823 elagolix Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940121296 linzagolix Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- PSBGROLQRNSAMY-UHFFFAOYSA-N n-(3-chlorophenyl)-4-methyl-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzamide Chemical compound C1=C(C#CC2=CN3N=CC=C3N=C2)C(C)=CC=C1C(=O)NC1=CC=CC(Cl)=C1 PSBGROLQRNSAMY-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229950004238 relugolix Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- PPPHYGCRGMTZNA-UHFFFAOYSA-M trifluoromethyl sulfate Chemical compound [O-]S(=O)(=O)OC(F)(F)F PPPHYGCRGMTZNA-UHFFFAOYSA-M 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to a series of thienopyrimidinedione compounds and their applications, in particular to the compounds represented by formula (II) and their pharmaceutically acceptable salts.
- GnRH gonadotropin-releasing hormone, gonadotropin-releasing hormone
- gonadotropin-releasing hormone is a decapeptide hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) synthesized by hypothalamic brain neuroendocrine cells, It is a central regulator in the endocrine nervous system.
- LH and FSH luteinizing hormone and follicular estrogen
- the pituitary-gonadal axis plays an important role.
- LH and FSH bind to receptors on specific cells of the ovary or testis to stimulate steroid production.
- the presence of steroids aggravates the conditions of endometriosis, uterine fibroids, and prostate cancer, requiring long-acting peptide GnRH receptor agonists or antagonists for control therapy.
- GnRH receptor agonist or antagonist compounds have many problems, such as oral absorption, dosage form, dose volume, drug stability, sustained action, and metabolic stability. Small molecule compounds can be administered orally, which is convenient and quick, and has obvious advantages. GnRH receptor antagonists directly inhibit the hypothalamus-pituitary-ovarian axis by competitively binding to GnRH receptors, blocking the binding of GnRH to the receptors, thereby inhibiting the secretion of follicle-stimulating hormone and luteinizing hormone, and reducing estrogen levels. Fast and less side effects.
- the present invention provides a novel thienopyrimidinedione GnRH receptor antagonist, and this kind of structure has significant inhibitory activity on GnRH receptor.
- the present invention provides a compound represented by formula (II) or a pharmaceutically acceptable salt thereof,
- R 2 and R 3 are each independently selected from H, F, Cl, Br, I and C 1-3 alkyl optionally substituted with 1 , 2 or 3 R b ;
- Each R 4 is independently selected from F, Cl, Br, I, C 1-3 alkoxy, -OC 3-6 cycloalkyl and C 3-6 cycloalkyl, the C 1-3 alkoxy , -OC 3-6 cycloalkyl and C 3-6 cycloalkyl are each independently optionally substituted with 1, 2 or 3 R c ;
- Ring B selected from 5-6 membered heterocyclyl optionally substituted with 1 , 2 or 3 F;
- R 6 is selected from H and C 1-3 alkyl optionally substituted with 1 , 2 or 3 F;
- R 7 is selected from C 1-3 alkyl optionally substituted with 1 , 2 or 3 F;
- n is selected from 1, 2, 3 and 4;
- n 0, 1 and 2;
- Ra , Rb , and Rc is independently selected from H, F, Cl, Br, and I, respectively.
- Other variables are as defined in the present invention.
- R2 is selected from H, F, Cl and CH3 , said CH3 is optionally substituted with 1, 2 or 3 F, other variables are as defined in the present invention.
- R3 is selected from H, F, Cl and CH3 , said CH3 is optionally substituted with 1, 2 or 3 F, other variables are as defined in the present invention.
- each of the above R 2 and R 3 is independently selected from H, and other variables are as defined herein.
- the above R 4 is selected from F, Cl, -OCH 3 , -OCH 2 CH 3 , -O-cyclopropyl, -O-cyclobutyl, cyclopropyl and cyclobutyl, so
- the -OCH 3 , -OCH 2 CH 3 , -O-cyclopropyl, -O-cyclobutyl, cyclopropyl and cyclobutyl are each independently optionally substituted with 1, 2 or 3 F, other variables such as as defined in the present invention.
- R 4 is selected from F, Cl, -OCH 3 , -OCH 2 CH 3 , Cyclopropyl and cyclobutyl, other variables are as defined herein.
- R4 is selected from F and -OCH3 , other variables are as defined in the present invention.
- R4 is selected from F and -OCH3 , and other variables are as defined in the present invention.
- R 1 and R 2 are linked together to form said Each independently is optionally substituted with 1, 2 or 3 F, other variables are as defined herein.
- R 1 and R 2 are linked together to form Other variables are as defined in the present invention.
- R 1 and R 2 are linked together to form Other variables are as defined in the present invention.
- R 1 and R 2 are linked together to form Other variables are as defined in the present invention.
- the above-mentioned compound or a pharmaceutically acceptable salt thereof the compound of which is selected from,
- R 1 , R 2 , R 3 , R 4 and n are as defined in the present invention.
- the above-mentioned compound or a pharmaceutically acceptable salt thereof the compound of which is selected from,
- R 5 is selected from C 1-3 alkyl optionally substituted with 1 , 2 or 3 R a ;
- Ring A is selected from C 3-6 cycloalkyl optionally substituted with 1, 2 or 3 R a ;
- p is selected from 0 and 1;
- Ring B, R 2 , R 3 , R 4 , n and Ra are as defined in the present invention.
- the above-mentioned compound or a pharmaceutically acceptable salt thereof the compound of which is selected from,
- R 5 is selected from C 1-3 alkyl optionally substituted with 1 , 2 or 3 R a ;
- Ring A is selected from C 3-6 cycloalkyl optionally substituted with 1, 2 or 3 R a ;
- p is selected from 0 and 1;
- Ring B, R 2 , R 3 , R 4 , m, n and Ra are as defined in the present invention.
- the present invention also provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
- R 2 and R 3 are each independently selected from H, F, Cl, Br, I and C 1-3 alkyl optionally substituted with 1 , 2 or 3 R b ;
- Each R 4 is independently selected from F, Cl, Br, I, C 1-3 alkoxy, -OC 3-6 cycloalkyl and C 3-6 cycloalkyl, the C 1-3 alkoxy , -OC 3-6 cycloalkyl and C 3-6 cycloalkyl are optionally substituted with 1, 2 or 3 R c ;
- R1 and R2 are joined together to form ring B, wherein ring B is selected from
- n is selected from 1, 2, 3 and 4;
- n 0, 1 and 2;
- Ra , Rb , and Rc is independently selected from H, F, Cl, Br, and I, respectively.
- the present invention also provides the following compounds or their pharmaceutically acceptable salts,
- the present invention also provides the use of the above compounds or their pharmaceutically acceptable salts in the preparation of medicines related to GnRH receptor antagonists.
- the above-mentioned GnRH receptor antagonist-related medicament is a medicament for preventing and/or treating endometriosis and/or uterine fibroids-related diseases.
- the above-mentioned GnRH receptor antagonist-related medicament is a medicament for preventing and/or treating prostate cancer-related diseases.
- the present invention also provides the following in vivo drug efficacy testing methods:
- Modeling The uterine horns of donor mice in interestrus were excised, opened longitudinally and the excised biopsies were cut to a size of 2 x 2 mm. Recipient mice were anesthetized with isoflurane gas and a 1 cm incision was made along the midline to expose the abdominal cavity. Endometriosis mice: four uterine fragments of the donor were sutured to the peritoneal wall of mice in estrus; sham-operated mice: abdominal fat fragments of similar size were sutured. The grafted tissue as well as the abdominal muscle and skin were sutured using 8-0 black silk suture. Sham group (sham operation group): the abdominal cavity of each Sham group was opened to transplant fat fragments, and the rest of the steps were the same.
- V 1 ectopic foci volume
- Sham group (sham operation group, 6 animals): normal feeding; Vehicle group (vehicle control group, 6 animals): vehicle was intragastrically administered once a day for 8 consecutive weeks, and the vehicle was 10% DMAC+10% solutol+80% saline; Compound group (6 animals): 100 mpk was intragastrically administered at 10:00 am every day for 8 consecutive weeks, and the vehicle was 10% DMAC+10% solutol+80% normal saline.
- the compound of the present invention has a significant inhibitory effect on the human gonadotropin-releasing hormone receptor, and has a significant anti-tumor effect on the human prostate cancer LNCaP clone FGC xenograft tumor model.
- the PK results show that the compound of the present invention is exposed in plasma. High, low clearance, long half-life, high oral bioavailability, exhibits excellent pharmacokinetic properties, and is a good molecule for the development of oral administration.
- the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue , without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- salts refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, and methanesulfonic acids; also include salts of amino acids such as arginine, etc. , and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base
- the pharmaceutically acceptable salts of the present invention can be synthesized from the acid or base containing parent compound by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to this within the scope of the invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- enantiomers or “optical isomers” refer to stereoisomers that are mirror images of each other.
- cis-trans isomer or “geometric isomer” result from the inability to rotate freely due to double bonds or single bonds to ring carbon atoms.
- diastereomer refers to a stereoisomer in which the molecule has two or more chiral centers and the molecules are in a non-mirror-image relationship.
- tautomer or “tautomeric form” refers to isomers of different functional groups that are in dynamic equilibrium and are rapidly interconverted at room temperature.
- a chemical equilibrium of tautomers can be achieved if tautomers are possible (eg, in solution).
- proton tautomers also called prototropic tautomers
- Valence tautomers include interconversions by recombination of some bonding electrons.
- keto-enol tautomerization is the interconversion between two tautomers, pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- the terms “enriched in one isomer”, “enriched in isomers”, “enriched in one enantiomer” or “enriched in one enantiomer” refer to one of the isomers or pairs
- the enantiomer content is less than 100%, and the isomer or enantiomer content is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or Greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
- isomeric excess or “enantiomeric excess” refer to the difference between two isomers or relative percentages of two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80% .
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with deuterium, and the bonds formed by deuterium and carbon are stronger than those formed by ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs can reduce toxic side effects and increase drug stability. , enhance the efficacy, prolong the biological half-life of drugs and other advantages. All transformations of the isotopic composition of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
- substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the specified atom is normal and the substituted compound is stable.
- oxygen it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted, and unless otherwise specified, the type and number of substituents may be arbitrary on a chemically achievable basis.
- any variable eg, R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, with independent options for R in each case.
- combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- any one or more sites in the group can be linked to other groups by chemical bonds.
- connection method of the chemical bond is not located, and there is an H atom at the linkable site, when the chemical bond is connected, the number of H atoms at the site will be correspondingly reduced with the number of chemical bonds connected to the corresponding valence. the group.
- the chemical bond connecting the site to other groups can be represented by straight solid line bonds straight dotted key or wavy lines express.
- a straight solid bond in -OCH 3 indicates that it is connected to other groups through the oxygen atom in this group;
- the straight dashed bond in the group indicates that it is connected to other groups through the two ends of the nitrogen atom in the group;
- the wavy line in the phenyl group indicates that it is connected to other groups through the 1 and 2 carbon atoms in the phenyl group;
- C 1-3 alkyl by itself or in combination with other terms denotes a straight or branched chain saturated hydrocarbon radical consisting of 1 to 3 carbon atoms, respectively.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (eg methyl), divalent (eg methylene) or multivalent (eg methine) .
- Examples of C1-3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- C 1-3 alkoxy by itself or in combination with other terms, respectively, refers to those alkyl groups containing 1 to 3 carbon atoms attached to the remainder of the molecule through an oxygen atom.
- the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy and the like. Examples of C 1-3 alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
- C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which are monocyclic and bicyclic ring systems, said C 3-6 cycloalkyl including C 3-5 , C 4-5 and C 5-6 cycloalkyl and the like; it may be monovalent, divalent or polyvalent.
- Examples of C3-6 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- the term "5- to 6-membered heterocyclyl” by itself or in combination with other terms denotes a saturated or unsaturated monocyclic group consisting of 5 or 6 ring atoms, respectively, of which 1, 2, 3 or 4 Ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, where the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (ie, NO and S(O) p , where p is 1 or 2). Furthermore, with respect to the "5-6 membered heterocyclyl", a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule.
- the 5-6 membered heterocyclic group includes 5- and 6-membered heterocycloalkyl, heterocycloalkenyl, and heteroaryl.
- 5-6 membered heterocyclyl groups include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothiophen-2-yl and Tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), di
- aromatic ring is a cyclic group having a conjugated pi-electron system, the atoms of which are covered by a cloud of delocalized pi-electrons.
- the structural formula when it conforms to the valence state and covalent bonding rules, it can be written in the form of alternating single and double bonds, or it can be written as represents the delocalized ⁇ electron cloud.
- the structural formula The structures represented are all the same, the structural formula The structures represented are all the same. It can be a monocyclic or fused polycyclic ring system, wherein each ring is aromatic. Unless otherwise specified, the ring optionally contains 0, 1 or more heteroatoms independently selected from O, S and N.
- Cn-n+m or Cn - Cn+m includes any particular instance of n to n+ m carbons, eg C1-12 includes C1 , C2 , C3, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , also including any range from n to n+ m , eg C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; in the same way, n yuan to n +m-membered means that the number of atoms in the ring is from n to n+m, for example, 3-12-membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membere
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments enumerated below, embodiments formed in combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
- the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction method (SXRD), the cultured single crystal is collected by Bruker D8 venture diffractometer, the light source is CuK ⁇ radiation, and the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- SXRD single crystal X-ray diffraction method
- the cultured single crystal is collected by Bruker D8 venture diffractometer
- the light source is CuK ⁇ radiation
- the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- DMSO dimethyl sulfoxide
- MeOH stands for methanol
- ACN stands for acetonitrile
- DEA diethylamine
- CO 2 stands for carbon dioxide
- DMAC N,N-dimethylacetamide
- Solutol stands for polyethylene glycol-15 hydroxystearate
- psi stands for pounds force per square inch
- PEG stands for polyethylene glycol.
- the solvent used in the present invention is commercially available.
- Compounds are named according to conventional nomenclature in the art or are used Software naming, commercially available compounds use supplier catalog names.
- reaction solution was added with 50 mL of water, extracted twice with 50 mL of ethyl acetate each time, the organic phases were combined, washed with 50 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness, and ethyl acetate (50 mL) was added.
- mL petroleum ether (50 mL), beating and stirring at 30° C. for 30 minutes, filtered, and the filter cake was dried under reduced pressure to obtain compound 1f.
- reaction solution was filtered through celite, and the filter cake was washed with dichloromethane (10 mL ⁇ 5), then water (10 mL) was added to the filtrate, extracted with dichloromethane (10 mL ⁇ 3), and the organic phases were combined , washed with water (10 mL ⁇ 2), washed with brine (10 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 1j.
- Potassium monopersulfate (251.15 mg, 408.53 ⁇ mol) was added to water (2 mL) and stirred at 28° C. until potassium monopersulfate was completely dissolved.
- the aqueous phase was extracted with ethyl acetate (10 mL ⁇ 5), the combined organic phases were washed with water (10 mL ⁇ 5) and brine (10 mL), the collected organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated.
- reaction system was poured into 10 mL of water, extracted with ethyl acetate (20 mL ⁇ 3), and the combined organic phases were washed with water (10 mL ⁇ 3) and brine (10 mL ⁇ 3).
- reaction solution was added with water (500 mL), extracted with ethyl acetate twice, 100 mL each time, the combined organic phases were washed twice with water, 200 mL each time, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, After filtration, the filtrate was concentrated to dryness under reduced pressure, ethyl acetate (5 mL) and petroleum ether (50 mL) were added, stirred at 30° C. for 30 minutes, filtered, and the filter cake was dried under reduced pressure to obtain compound 7b.
- reaction solution was added with 10 mL of water, extracted twice with 10 mL of ethyl acetate each time, and the organic phases were combined, washed with 10 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain compound 7p.
- reaction solution was filtered with celite, and the filter cake was washed with dichloromethane (10 mL ⁇ 5), then water (10 mL) was added to the filtrate, extracted with dichloromethane (10 mL ⁇ 3), the organic phases were combined, and water ( 10 mL ⁇ 2), washed with brine (10 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 81.
- GnRH/HEK293 human embryonic kidney cell 293 cultured cells in the logarithmic growth phase, wash them with DPBS (Dulbecco's phosphate buffered saline) buffer, add an appropriate amount of 0.05% EDTA (ethylenediaminetetraacetic acid)-trypsin and place them at 37 Digest in a carbon dioxide incubator at °C, remove the cells for 1-2 minutes and add the medium to terminate the digestion.
- DPBS Dens phosphate buffered saline
- EDTA ethylenediaminetetraacetic acid
- the cells were collected by centrifugation, and seeded into a 384-well poly-lysine-coated cell plate at a density of 20,000 cells per well, 20 ⁇ L, and incubated overnight in a 5% CO 2 incubator at 37°C.
- test compounds and appropriate concentrations of reference compounds were diluted in 4-fold 10-point series with ECHO and 900 nL were transferred to compound plates.
- Run the FLIPR instrument software add 10 ⁇ L of test and reference compounds to the cell plate according to the set program, and read the fluorescent signal. Then 10 ⁇ L of agonist at 6 ⁇ EC 80 concentration was added to the cell plate, and the fluorescent signal was read.
- the compound of the present invention has a significant inhibitory effect on the human gonadotropin-releasing hormone receptor.
- Each test compound was mixed with DMAC separately, vortexed for 2 minutes, and the DMAC solution of the test compound was mixed and vortexed for 2 minutes to prepare a clear solution of 10 mg/mL. Take 0.0600 mL of 10 mg/mL solution and add 0.300 mL of Solutol, vortex for 2 minutes, then add 2.400 mL of normal saline, and vortex for 2 minutes to obtain a clear solution of 0.2 mg/mL, which is used for PO group administration.
- mice Four male CD-1 mice were divided into two groups. The animals in the first group were given a single intravenous dose of 0.5 mg/kg, the vehicle was 10% DMAC/10% Solutol/80% normal saline, and the administration volume was 5 mL/kg. The animals in the second group were given a single oral gavage of 2 mg/kg of the test compound, the oral vehicle was 10% DMAC/10% Solutol/80% normal saline, and the oral volume was 10 mL/kg.
- Whole blood was collected at 0.033 (iv injection only), 0.083, 0.25, 0.5, 1, 2, 4 and 12 hours post-dose. Whole blood was centrifuged at 3200g at 2-8°C for 10 min to obtain plasma, the concentration of the test compound in plasma was determined by LC/MS/MS method, and the pharmacokinetic parameters were calculated by Phoenix WinNonlin software.
- test results are shown in Table 2.
- IV intravenous injection
- PO oral
- C 0 initial blood drug concentration
- C max maximum drug concentration in systemic circulation
- T max time required to reach C max
- T 1/2 half-life
- V dss apparent volume of distribution
- Cl clearance rate
- AUC 0-last area under the curve at the time of drug administration.
- the compound of the present invention has high exposure in plasma, low clearance rate, long half-life and high oral bioavailability, exhibits excellent pharmacokinetic properties, and is a good molecule for developing oral administration.
- mice Male CB17-SCID mice were subcutaneously inoculated with LNCaP clone FGC human prostate cancer cell line, and on the 17th day after inoculation (the day of inoculation was taken as day 0), they were randomly divided into an operation group and a non-surgery group according to tumor volume and body weight, and the operation group was divided into two groups. (6 animals) were subjected to castration, and on day 20 after inoculation, animals in the non-operated group were randomly divided into non-operated control and compound groups (6 animals per group) according to tumor volume and body weight, and were performed as described below. Medication treatment.
- Group 1 (non-surgical control group): start administration on the afternoon of the 20th day after grouping, once a day, intragastric administration of vehicle (5% DMSO + 40% PEG400 + 10% solutol) at a dose of 0.1 mL/10 g body weight +45% water).
- Group 2 The administration started in the afternoon after the grouping on the 20th day of inoculation, once a day, the vehicle (5% DMSO + 40% PEG400 + 10% solutol was administered by intragastric administration at a dose of 0.1 mL/10 g body weight) +45% water).
- Group 3 (Compound 1): After inoculation on the 20th day, the administration started in the afternoon of the same day, once a day, compound 1 was administered by intragastric administration at a dose of 100 mg/kg body weight, and the vehicle was 10% DMAC+10% solutol+80% physiological brine.
- Tumor volumes were measured and mice were weighed twice a week during the experiment, and tumor proliferation rates were calculated.
- tumor volume length ⁇ width2/ 2
- tumor proliferation rate tumor volume of treatment group/tumor volume of non-operation control group ⁇ 100%.
- the compound of the present invention has significant antitumor effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了一系列噻吩并嘧啶二酮类化合物及其应用,具体公开了式(II)所示化合物及其药学上可接受的盐。
Description
本发明主张如下优先权:
CN202110205200.0,申请日2021年02月23日;
CN202210128005.7,申请日2022年02月10日。
本发明涉及一系列噻吩并嘧啶二酮类化合物及其应用,具体涉及式(II)所示化合物及其药学上可接受的盐。
GnRH(gonadotropin-releasing hormone,促性腺素释放素)是由下丘脑脑神经内分泌细胞合成的十肽激素(pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2),是内分泌神经系统中的中枢调节因子。它通过下丘脑垂体门脉循环系统到达垂体,与垂体前叶的GnRH受体细胞结合,促进黄体生成素(LH)和卵泡雌激素(FSH)的分泌,调节卵巢和黄体的正常发育,在下丘脑-垂体-性腺轴发挥重要作用。LH和FSH与卵巢或睾丸的特异性细胞上受体结合,刺激类固醇的生成。类固醇的存在,使得子宫内膜异位症、子宫肌瘤和前列腺癌等病情加重,需要给予长效肽内GnRH受体激动剂或拮抗剂进行控制治疗。
多肽类的GnRH受体激动剂或拮抗剂化合物存在许多问题,如口服吸收性、剂型、剂量体积、药物稳定性、持续作用以及代谢稳定性等问题。小分子化合物可以口服给药,方便快捷,优势明显。GnRH受体拮抗剂通过竞争性结合GnRH受体,阻断GnRH与受体结合,直接抑制下丘脑-垂体-卵巢轴,进而抑制卵泡刺激素和黄体生成素的分泌,降低雌激素水平,起效快,副作用小。
尽管在这些领域有一些有意义的临床试验已在进行,如小分子GnRH受体拮抗剂研发处于最靠前的Elagolix、Relugolix、Linzagolix和SKI2670,但是目前还需要继续研究开发更加有效的小分子GnRH受体拮抗剂。
发明内容
本发明提供了一种新型的噻吩并嘧啶二酮类GnRH受体拮抗剂,此类结构对GnRH受体具有显著的抑制活性。
本发明提供了式(II)所示化合物或其药学上可接受的盐,
其中,
R
1选自C
3-6环烷基、-S(=O)
m-C
1-3烷基、-S(=O)
m-C
3-6环烷基和-O-C
3-6环烷基,所述C
3-6环烷基、-S(=O)
m-C
1-3烷基、-S(=O)
m-C
3-6环烷基和-O-C
3-6环烷基分别独立地任选被1、2或3个R
a取代;
R
2和R
3各自独立地选自H、F、Cl、Br、I和C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
b取代;
各R
4分别独立地选自F、Cl、Br、I、C
1-3烷氧基、-O-C
3-6环烷基和C
3-6环烷基,所述C
1-3烷氧基、-O-C
3-
6环烷基和C
3-6环烷基分别独立地任选被1、2或3个R
c取代;
或者,R
1和R
2与它们连接的原子一起形成环B,环B选自5-6元杂环基,所述5-6元杂环基任选被1、2或3个F取代;
R
8选自-C(=O)OR
6和-P(=O)(R
7)OR
6;
R
6选自H和C
1-3烷基,所述C
1-3烷基任选被1、2或3个F取代;
R
7选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个F取代;
n选自1、2、3和4;
m选自0、1和2;
各R
a、R
b和R
c分别独立地选自H、F、Cl、Br和I。
在本发明的一些方案中,上述R
1选自环丙基、环丁基、-S(=O)
m-C
1-3烷基和-O-环丙基,所述环丙基、环丁基、-S(=O)
m-C
1-3烷基和-O-环丙基分别独立地任选被1、2或3个R
a取代,其他变量如本发明所定义。
在本发明的一些方案中,上述R
1选自-S(=O)
m-C
1-3烷基,所述-S(=O)
m-C
1-3烷基任选被1、2或3个R
a取代,其他变量如本发明所定义。
在本发明的一些方案中,上述R
1选自-SCH
3、-SCF
3、-SCF
3、-SCH
2CH
3、-SCH
2CF
3、-S(=O)CH
3和-S(=O)
2CH
3,其他变量如本发明所定义。
在本发明的一些方案中,上述R
1选自-SCH
3、-S(=O)CH
3和-S(=O)
2CH
3,其他变量如本发明所定义。
在本发明的一些方案中,上述R
2选自H、F、Cl和CH
3,所述CH
3任选被1、2或3个F取代,其他变量如本发明所定义。
在本发明的一些方案中,上述R
3选自H、F、Cl和CH
3,所述CH
3任选被1、2或3个F取代,其他变量如本发明所定义。
在本发明的一些方案中,上述R
2和R
3各自独立地选自H,其他变量如本发明所定义。
在本发明的一些方案中,上述R
4选自F、Cl、-OCH
3、-OCH
2CH
3、-O-环丙基、-O-环丁基、环丙基和环丁基,所述-OCH
3、-OCH
2CH
3、-O-环丙基、-O-环丁基、环丙基和环丁基分别独立地任选被1、2或3个F取代,其他变量如本发明所定义。
在本发明的一些方案中,上述R
4选自F和-OCH
3,其他变量如本发明所定义。
在本发明的一些方案中,上述R
8选自-C(=O)OH、-C(=O)OCH
3、-C(=O)OCH
2CH
3、-C(=O)OC(CH
3)
2、-P(=O)(CH
3)OH和-P(=O)(CH
3)OCH
3,其他变量如本发明所定义。
在本发明的一些方案中,上述R
8选自-C(=O)OH和-P(=O)(CH
3)OH,其他变量如本发明所定义。
在本发明的一些方案中,上述R
8选自-C(=O)OH,其他变量如本发明所定义。
在本发明的一些方案中,上述化合物或其药学上可接受的盐,其化合物选自,
其中,R
1、R
2、R
3、R
4和n如本发明所定义。
在本发明的一些方案中,上述化合物或其药学上可接受的盐,其化合物选自,
其中,
R
5选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
a取代;
环A选自C
3-6环烷基,所述C
3-6环烷基任选被1、2或3个R
a取代;
p选自0和1;
环B、R
2、R
3、R
4、n和R
a如本发明所定义。
在本发明的一些方案中,上述化合物或其药学上可接受的盐,其化合物选自,
其中,
R
5选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
a取代;
环A选自C
3-6环烷基,所述C
3-6环烷基任选被1、2或3个R
a取代;
p选自0和1;
环B、R
2、R
3、R
4、m、n和R
a如本发明所定义。
本发明还提供了式(I)所示化合物或其药学上可接受的盐,
其中,
R
1选自C
3-6环烷基、-S(=O)
m-C
1-3烷基、-S(=O)
m-C
3-6环烷基和-O-C
3-6环烷基,所述C
3-6环烷基、-S(=O)
m-C
1-3烷基、-S(=O)
m-C
3-6环烷基和-O-C
3-6环烷基任选被1、2或3个R
a取代;
R
2和R
3各自独立地选自H、F、Cl、Br、I和C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
b取代;
各R
4分别独立地选自F、Cl、Br、I、C
1-3烷氧基、-O-C
3-6环烷基和C
3-6环烷基,所述C
1-3烷氧基、-O-C
3-
6环烷基和C
3-6环烷基任选被1、2或3个R
c取代;
n选自1、2、3和4;
m选自0、1和2;
各R
a、R
b和R
c分别独立地选自H、F、Cl、Br和I。
本发明还有一些方案由上述变量任意组合而来。
本发明还提供了下列所示化合物或其药学上可接受的盐,
本发明还提供了上述化合物或其药学上可接受的盐在制备GnRH受体拮抗剂相关的药物中的应用。
本发明的一些方案中,上述GnRH受体拮抗剂相关的药物是用于预防和/或治疗子宫内膜异位症和/或子宫肌瘤相关疾病的药物。
本发明的一些方案中,上述GnRH受体拮抗剂相关的药物是用于预防和/或治疗前列腺癌相关疾病的药物。
本发明还提供了下列体内药效测试方法:
实验目的:本发明化合物在小鼠子宫内膜异位症模型中的药效评价。
试验方案:
2.1主要试剂及耗材
C57BL6/J雌性小鼠,游标卡尺(ARZ-1331),8-0缝合线,体式显微镜。
2.2实验步骤
8周龄雌性C57BL6/J雌性小鼠动物动情周期检测:阴道涂片观察,由于整个动情周期大约4天,根据 实际涂片结果选择在实验当天符合动情具体周期的小鼠进行实验。
建模:处于动情间期的供体小鼠的子宫角切下,纵向打开并对切下来的活组织切片剪成2×2mm大小。用异氟烷气体麻醉受体小鼠,并沿中线切口1cm以暴露腹腔。子宫内膜异位症小鼠:供体的四个子宫碎片缝合到处于发情期小鼠的腹膜壁上;假手术小鼠:缝合大小相似的腹部脂肪碎片。使用8-0黑色丝线缝合移植的组织以及腹肌和皮肤。Sham组(假手术组):每只Sham组都打开腹腔移植脂肪碎片,其余步骤都一致。
建模4周后二次开腹,使用游标卡尺测量并计算异位灶体积(V
1)确定造模成功。选取V
1较为均一的12只小鼠分为2组,每组6只:Vehicle(溶媒对照组)、药物组。
Sham组(假手术组,6只):正常饲养;Vehicle组(溶媒对照组,6只):每天灌胃一次溶媒,连续8周,溶媒为10%DMAC+10%solutol+80%生理盐水;化合物组(6只):每天上午10:00灌胃100mpk,连续8周,溶媒为10%DMAC+10%solutol+80%生理盐水。
给药8周后小鼠取材:使用游标卡尺测量并计算异位灶体积(V
2),计算抑制率。计算公式:异位灶体积V=π/6×length×width×height,length表示异位灶的长,width表示异位灶的宽,height表示异位灶的高;
技术效果
本发明化合物对人源促性腺激素释放激素受体具有显著的抑制作用,在人前列腺癌LNCaP clone FGC异种移植瘤模型上具有显著的抗肿瘤效果,PK结果显示本发明化合物在血浆中的暴露量高,清除率低,半衰期长,口服生物利用度高,展现了优秀的药代动力学性质,是良好的开发口服给药的分子。
定义和说明
除非另有说明,本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。
这里所采用的术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机胺或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的 惰性溶剂中用足够量的酸与这类化合物接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐,所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸,碳酸氢根,磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等;以及有机酸盐,所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸;还包括氨基酸(如精氨酸等)的盐,以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物,包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体,及其外消旋混合物和其他混合物,例如对映异构体或非对映体富集的混合物,所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物,均包括在本发明的范围之内。
除非另有说明,术语“对映异构体”或者“旋光异构体”是指互为镜像关系的立体异构体。
除非另有说明,术语“顺反异构体”或者“几何异构体”系由因双键或者成环碳原子单键不能自由旋转而引起。
除非另有说明,术语“非对映异构体”是指分子具有两个或多个手性中心,并且分子间为非镜像的关系的立体异构体。
除非另有说明,术语“互变异构体”或“互变异构体形式”是指在室温下,不同官能团异构体处于动态平衡,并能很快的相互转化。若互变异构体是可能的(如在溶液中),则可以达到互变异构体的化学平衡。例如,质子互变异构体(proton tautomer)(也称质子转移互变异构体(prototropic tautomer))包括通过质子迁移来进行的互相转化,如酮-烯醇异构化和亚胺-烯胺异构化。价键异构体(valence tautomer)包括一些成键电子的重组来进行的相互转化。其中酮-烯醇互变异构化的具体实例是戊烷-2,4-二酮与4-羟基戊-3-烯-2-酮两个互变异构体之间的互变。
除非另有说明,术语“富含一种异构体”、“异构体富集”、“富含一种对映体”或者“对映体富集”指其中一种异构体或对映体的含量小于100%,并且,该异构体或对映体的含量大于等于60%,或者大于等于70%,或者大于等于80%,或者大于等于90%,或者大于等于95%,或者大于等于96%,或者大于等于97%,或者大于等于98%,或者大于等于99%,或者大于等于99.5%,或者大于等于99.6%,或者大于等于99.7%,或者大于等于99.8%,或者大于等于99.9%。
除非另有说明,术语“异构体过量”或“对映体过量”指两种异构体或两种对映体相对百分数之间的差值。例如,其中一种异构体或对映体的含量为90%,另一种异构体或对映体的含量为10%,则异构体或对映体过量(ee值)为80%。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氚(
3H),碘-125(
125I)或C-14(
14C)。又例如,可用重氢取代氢形成氘代药物,氘与碳构成的键比普通氢与碳构成的键更坚固,相比于未氘化药物,氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本发明的化合物的所有同位素组成的变换,无论放射性与否,都包括在本发明的范围之内。
术语“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的,并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代,取代基可以包括重氢和氢的变体,只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧(即=O)时,意味着两个氢原子被取代。氧取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代,也可以不被取代,除非另有规定,取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时,其在每一种情况下的定义都是独立的。因此,例如,如果一个基团被0-2个R所取代,则所述基团可以任选地至多被两个R所取代,并且每种情况下的R都有独立的选项。此外,取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当一个连接基团的数量为0时,比如-(CRR)
0-,表示该连接基团为单键。
当其中一个变量选自单键时,表示其连接的两个基团直接相连,比如A-L-Z中L代表单键时表示该结构实际上是A-Z。
除非另有规定,当某一基团具有一个或多个可连接位点时,该基团的任意一个或多个位点可以通过化学键与其他基团相连。当该化学键的连接方式是不定位的,且可连接位点存在H原子时,则连接化学键时,该位点的H原子的个数会随所连接化学键的个数而对应减少变成相应价数的基团。所述位点与其他基团连接的化学键可以用直形实线键
直形虚线键
或波浪线
表示。例如-OCH
3中的直形实线键表示通过该基团中的氧原子与其他基团相连;
中的直形虚线键表示通过该基团中的氮原子的两端与其他基团相连;
中的波浪线表示通过该苯基基团中的1和2位碳原子与其他基团相连;
表示该哌啶基上的任意可连接位点可以通过1个化学键与其他基团相连,至少包括
这4种连接方式,即使-N-上画出了H原子,但是
仍包括
这种连接方式的基团,只是在连接1个化学键时,该位点的的H会对应减少1个变成相应的一价哌啶基。
除非另有规定,术语“C
1-3烷基”本身或者与其他术语联合分别表示直链或支链的由1至3个碳原子组成的饱和碳氢基团。所述C
1-3烷基包括C
1-2和C
2-3烷基等;其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C
1-3烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)等。
除非另有规定,术语“C
1-3烷氧基”本身或者与其他术语联合分别表示通过一个氧原子连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C
1-3烷氧基包括C
1-2、C
2-3、C
3和C
2烷氧基等。C
1-3烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(包括正丙氧基和异丙氧基)等。
除非另有规定,“C
3-6环烷基”表示由3至6个碳原子组成的饱和环状碳氢基团,其为单环和双环体系,所述C
3-6环烷基包括C
3-5、C
4-5和C
5-6环烷基等;其可以是一价、二价或者多价。C
3-6环烷基的实例包括,但不限于,环丙基、环丁基、环戊基、环己基等。
除非另有规定,术语“5-6元杂环基”本身或者与其他术语联合分别表示由5或6个环原子组成的饱和或不饱和的单环基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。此外,就该“5-6元杂环基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述5-6元杂环基包括5元和6元杂环烷基、杂环烯基、杂芳基。5-6元杂环基的实例包括但不限于吡咯基、吡唑基、咪唑基、吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)、四氢呋喃基(包括四氢呋喃-2-基等)、四氢吡喃基、哌啶基(包括1-哌啶基、2-哌啶基和3-哌啶基等)、哌嗪基(包括1-哌嗪基和2-哌嗪基等)、吗啉基(包括3-吗啉基和4-吗啉基等)、二噁烷基、二噻烷基、异噁唑烷基、异噻唑烷基、1,2-噁嗪基、1,2- 噻嗪基、六氢哒嗪基、
除非另有规定,术语“芳香性环”为具有共轭π电子体系的环状基团,其原子间被离域π电子云覆盖。在结构式中,在符合原子价态和共价键成键规则时,可以书写为单双键交替的形式,也可以用
表示离域π电子云。例如,结构式
所表示的结构均相同,结构式
所表示的结构均相同。其可以是单环或稠合多环体系,其中各个环均为芳香性的。除非另有规定,该环任选地包含0、1或多个独立选自O、S和N的杂原子。
除非另有规定,C
n-n+m或C
n-C
n+m包括n至n+m个碳的任何一种具体情况,例如C
1-12包括C
1、C
2、C
3、C
4、C
5、C
6、C
7、C
8、C
9、C
10、C
11、和C
12,也包括n至n+m中的任何一个范围,例如C
1-12包括C
1-
3、C
1-6、C
1-9、C
3-6、C
3-9、C
3-12、C
6-9、C
6-12、和C
9-12等;同理,n元至n+m元表示环上原子数为n至n+m个,例如3-12元环包括3元环、4元环、5元环、6元环、7元环、8元环、9元环、10元环、11元环、和12元环,也包括n至n+m中的任何一个范围,例如3-12元环包括3-6元环、3-9元环、5-6元环、5-7元环、6-7元环、6-8元环、和6-10元环等。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备,包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式,优选的实施方式包括但不限于本发明的实施例。
本发明的化合物可以通过本领域技术人员所熟知的常规方法来确认结构,如果本发明涉及化合物的绝对构型,则该绝对构型可以通过本领域常规技术手段予以确证。例如单晶X射线衍射法(SXRD),把培养出的单晶用Bruker D8 venture衍射仪收集衍射强度数据,光源为CuKα辐射,扫描方式:
扫描,收集相关数据后,进一步采用直接法(Shelxs97)解析晶体结构,便可以确证绝对构型。
本发明采用下述缩略词:DMSO代表二甲基亚砜;MeOH代表甲醇;ACN代表乙腈;DEA代表二乙胺;CO
2代表二氧化碳;DMAC代表N,N-二甲基乙酰胺;Solutol代表聚乙二醇-15羟基硬脂酸酯;psi代表磅力/平方英寸;PEG代表聚乙二醇。
下面通过实施例对本发明进行详细描述,但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明,其中也公开了其具体实施例方式,对本领域的技术人员而言,在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
实施例1
第一步
向化合物1a(顺丁烯二酸二甲酯,50克,346.92毫摩尔)和巯基乙酸甲酯(37.01克,348.68毫摩尔)的四氢呋喃(300毫升)溶液中加入哌啶(886.18毫克,10.41毫摩尔),混合物在25℃搅拌2小时。加入300毫升水,用乙酸乙酯萃取两次,每次200毫升,合并的有机相用200毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物1b。
1H NMR(400MHz,CDCl
3)δ=3.89-3.81(m,1H),3.76(s,3H),3.75(d,3H),3.69(s,3H),3.55-3.32(m,2H),3.00(m,1H),2.73(m,1H)。
第二步
在20℃以下,向甲醇(10毫升)中加入钠(2.78克,120.92毫摩尔),64℃以下搅拌至固体溶解,配置成甲醇钠甲醇溶液,冷却到20℃,加入到1b(10克,39.96毫摩尔)的四氢呋喃(20毫升)溶液中,反应液66℃氮气保护下搅拌3小时。加入异丙醚(100毫升),醋酸(1毫升),冷却到20℃,过滤,滤饼加入到磷酸(10毫升)和水(20毫升)的混合物中,用乙酸乙酯萃取两次,每次20毫升,合并的有机相用30毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物1c。
第三步
化合物1c(7.4克,33.91毫摩尔),吡啶(4.03克,50.89毫摩尔),羟胺盐酸盐(2.47克,35.57毫摩尔)的混合物在50℃搅拌2小时。反应液加入2毫升磷酸,20毫升水,用乙酸乙酯萃取两次,每次20毫升,合并有机层,20毫升饱和碳酸氢钠洗涤,20毫升饱和氯化钠水溶液洗一次,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物1d。
第四步
向化合物1d(5.2克,22.29毫摩尔)的醋酸(5毫升)中,加入4摩尔每升盐酸乙酸乙酯(52.00毫升),反应液在25℃下搅拌12小时。反应液过滤,滤饼减压干燥得到化合物1e的盐酸盐。
MS-ESI计算值[M+H-MeOH]
+:184.0,实测值184.1。
第五步
向化合物1e(2克,7.95毫摩尔,盐酸盐)的四氢呋喃(20毫升)和水(10毫升)中,加碳酸钾(1.65克,11.92毫摩尔),在5-10℃滴加氯甲酸苯酯(2.49克,15.89毫摩尔),反应液在5-10℃下搅拌1小时。反应液加入50毫升水,用乙酸乙酯萃取两次,每次50毫升,合并有机相,用50毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液浓缩干,加入乙酸乙酯(5毫升),石油醚(50毫升),30℃打浆搅拌30分钟,过滤,滤饼减压干燥得到化合物1f。
MS-ESI计算值[M+H]
+:336.1,实测值336.1。
第六步
在27℃下,向化合物1g(2,4-二氟-5-硝基苯酚,2克,11.42毫摩尔)的N,N-二甲基甲酰胺(10毫升)溶液中,分批次加入碳酸钾(3.16克,22.85毫摩尔)。然后将甲硫醇钠(880.68毫克,12.56毫摩尔)加入到该反应体系中,该反应体系在27℃下搅拌2小时。向该反应体系中加入2摩尔/升的盐酸调节pH至6。向反应体系中加入水(30毫升),用乙酸乙酯萃取(30毫升×3),合并有机相用水洗涤(10毫升×6)。收集有机相用无水硫酸钠干燥,过滤,过滤,滤液浓缩得到化合物1h。
1H NMR(400MHz,DMSO-d
6)δ=10.87(s,1H),7.43(d,J=6.6Hz,1H),7.22(d,J=12.4Hz,1H),2.49(br s,3H)。
第七步
向化合物3-氯甲基-1,2-二氟-4-甲氧基苯(454.96毫克,2.3毫摩尔)和化合物1h(400毫克,1.97毫摩尔)的甲苯(3毫升)溶液中加入四丁基溴化铵(63.46毫克,196.86微摩尔)。然后将氢氧化钠(118.12毫克,2.95毫摩尔)的水(0.3毫升)溶液加入到反应体系中。该混合物在50℃下搅拌12小时。将该反应液倒入30毫升水中,用乙酸乙酯萃取(20毫升×3),合并有机相用水洗涤(10毫升×6)。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩,柱层析纯化(硅胶,石油醚:乙酸乙酯=1:0-20:1)得到化合物1i。
1H NMR(400MHz,CDCl
3)δ=7.81(d,J=6.4Hz,1H),7.16(q,J=9.2Hz,1H),6.90(d,J=11.6Hz,1H),6.70-6.62(m,1H),5.30(d,J=1.2Hz,2H),3.94-3.89(m,3H),2.44(s,3H)。
第八步
向化合物1i(163毫克,453.63微摩尔)的乙醇(5毫升)和水(0.5毫升)溶液中,加入铁粉(126.88毫克,2.27毫摩尔)和氯化铵(14.56毫克,272.18微摩尔)。该混合物在85℃下搅拌1小时。将该反应液用硅藻土过滤,滤饼用二氯甲烷洗涤(10毫升×5),然后向滤液中加入水(10毫升),用二氯甲烷萃取(10毫升×3),合并有机相,用水洗涤(10毫升×2),食盐水洗涤(10毫升×2),无水硫酸钠干燥,过滤,滤液浓缩得到化合物1j。
MS-ESI计算值[M+H]
+:330.1,实测值330.1。
第九步
向化合物1j(117毫克,355.26微摩尔)的四氢呋喃(4毫升)溶液中,加入化合物1f(119.13毫克,355.26微摩尔)和三乙胺(35.95毫克,355.26微摩尔)。该混合物在70℃下搅拌10小时。将该反应体系降温至27℃,向该反应体系中加入化合物1f(65毫克,193.84微摩尔)和三乙胺(35.95毫克,355.26微摩尔)。该混合物在70℃下搅拌5小时。将该反应液中倒入30毫升水中,用乙酸乙酯萃取(50毫升×5),合并有机相用水(20毫升×5)洗涤,饱和食盐水(20毫升)洗涤,并用无水硫酸钠干燥,过滤,滤液浓缩后粗品制备色谱纯化(硅胶,石油醚:乙酸乙酯=2:1)得到化合物1k。
MS-ESI计算值[M+H]
+:571.1,实测值571.1。
第十步
向化合物1k(100毫克,175.27微摩尔)的四氢呋喃(1毫升)和甲醇(1毫升)的溶液中加入一水合氢氧化锂(44.13毫克,175.27微摩尔)的水溶液(0.5毫升),该混合物在28℃下搅拌1小时。向该反应液中加入1摩尔/升的稀盐酸调节pH至6左右,然后用乙酸乙酯萃取(5毫升×5),合并有机相用水(5毫升×3)洗涤,收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后粗品经制备色谱纯化(硅胶,二氯甲烷:甲醇=10:1)得到化合物1。
MS-ESI计算值[M+H]
+:525.0,实测值525.0。
1H NMR(400MHz,DMSO-d
6)δ=11.98(br s,1H),7.56-7.40(m,1H),7.38-7.26(m,2H),7.18(d,J=10.4Hz,1H),6.92(br d,J=9.2Hz,1H),5.03(s,2H),3.82(s,3H),2.40(s,3H)。
实施例2和3
第一步
向化合物1k(165毫克,289.19微摩尔)的四氢呋喃(1毫升)和甲醇(1毫升)溶液中,加入甲醇钠(31.24毫克,578.38微摩尔),该反应体系在28℃下搅拌0.5小时。向反应体系中加入醋酸(2毫升)和水(10毫升),用乙酸乙酯萃取(10毫升×2),合并有机相用食盐水(10毫升)洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩得到化合物2a。
MS-ESI计算值[M+H]
+:539.1,实测值539.1。
1H NMR(400MHz,CDCl
3)δ=10.34(s,1H),7.12(q,J=9.2Hz,1H),6.98(d,J=10.0Hz,1H),6.93(d,J=6.4Hz,1H),6.87(s,1H),6.64-6.57(m,1H),5.13(dd,J=1.6,4.4Hz,2H),3.96(s,3H),3.81(s,3H),2.39(s,3H)。
第二步
将单过硫酸氢钾(251.15毫克,408.53微摩尔)加入水(2毫升)中,28℃下搅拌直至单过硫酸氢钾完全溶解。然后在快速搅拌下,将化合物2a(88毫克,163.41微摩尔)的乙腈(1毫升)溶液逐滴加入到反应体系中。该混合物在28℃下搅拌18.5小时。将该反应体系倒入水(10毫升)中。该水相用乙酸乙酯萃取(10毫升×5),合并有机相用水(10毫升×5)洗涤,食盐水(10毫升)洗涤,收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后粗品经制备色谱纯化(硅胶,二氯甲烷:甲醇=15:1)得到化合物2b和2c。
化合物2b:MS-ESI计算值[M+H]
+:571.0,实测值571.1;
化合物2c:MS-ESI计算值[M+H]
+:555.0,实测值555.1。
第三步
向化合物2b(23毫克,40.31微摩尔)的四氢呋喃(1毫升)和甲醇(1毫升)的溶液中加入氢氧化钠(4.84毫克,120.94微摩尔)的水溶液(0.5毫升),该混合物在28℃下搅拌1.5小时。向该反应液中加入1摩尔/升稀盐酸调节pH至6左右,然后用乙酸乙酯萃取(5毫升×5),合并有机相用水洗涤(5毫升×3), 收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后粗品经制备色谱纯化(硅胶,二氯甲烷:甲醇=10:1),再经高效液相色谱制备分离(色谱柱:3_Phenomenex Luna C18 75×30mm*3μm;流动相:[水(0.05%盐酸)-乙腈];乙腈%:37%-57%)得到化合物2。
MS-ESI计算值[M+H]
+:557.0,实测值557.0。
1H NMR(400MHz,DMSO-d
6)δ=12.10(br s,1H),7.84(d,J=5.2Hz,1H),7.80(d,J=8.4Hz,1H),7.53(q,J=9.6Hz,1H),7.34(br s,1H),6.96(br d,J=9.4Hz,1H),5.19(s,2H),3.82(s,3H),3.26-3.24(m,3H)。
第四步
向化合物2c(61毫克,110.01微摩尔)的四氢呋喃(1毫升)和甲醇(1毫升)的溶液中加入氢氧化钠(13.20毫克,331.02微摩尔)的水溶液(0.5毫升),该混合物在28℃下搅拌1.5小时。向该反应液中加入1摩尔/升稀盐酸调节pH至6左右,然后用乙酸乙酯萃取(5毫升×5),合并有机相用水洗涤(5毫升×3),收集有机相用无水硫酸钠干燥,过滤,滤液浓缩,粗品经经制备色谱纯化(硅胶,二氯甲烷:甲醇=8:1)得到化合物3。
MS-ESI计算值[M+H]
+:541.0,实测值541.1。
1H NMR(400MHz,DMSO-d
6)δ=14.31-14.25(m,1H),12.10(br d,J=7.6Hz,1H),7.66(dd,J=2.0,5.6Hz,1H),7.59-7.55(m,1H),7.55-7.49(m,1H),7.39(d,J=2.8Hz,1H),6.98-6.94(m,1H),5.20-5.15(m,1H),5.11-5.07(m,1H),3.83(s,3H),2.75(s,3H)。
实施例4
第一步
在20℃下,向化合物4a(5-氟-2-甲氧基苯酚,4.5克,31.66毫摩尔)的N,N-二甲基乙酰胺(30毫升)溶液中加入氢氧化钾(3.55克,63.32毫摩尔),逐滴加入溴乙酸醛(9.36克,47.49毫摩尔)。该反应体系升温至160℃并在160℃下搅拌4小时。向反应体系中加入水(10毫升),用乙酸乙酯(20毫升×3),合并有机相用10%氢氧化钠水溶液(10毫升×2)。收集有机相用无水硫酸钠干燥,过滤,滤液减压浓缩得到化合物4b。
1H NMR(400MHz,CDCl
3)δ=6.82-6.76(m,1H),6.74-6.68(m,1H),6.64-6.56(m,1H),4.92-4.80(m,1H),4.05-4.00(d,J=20.0,2H),3.83(s,3H),3.79-3.73(m,2H),3.68-3.62(m,2H),1.24(m,6H)。
第二步
向化合物4b(9.72克,37.63毫摩尔)的甲苯(110毫升)溶液中,加入多聚磷酸(972毫克,37.63毫摩尔)。该混合物在110℃下搅拌2.5小时。向该反应液中加入水(10毫升),用乙酸乙酯(20毫升×3),合并有机相用食盐水(10毫升×3)洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析分离(硅胶,石油醚:乙酸乙酯=1:0-400:1)得到化合物4c。
1H NMR(400MHz,CDCl
3)δ=7.61(d,J=2.4Hz,1H),6.88-6.86(d,J=2.0Hz,1H),6.85-6.82(d,J=9.2Hz,1H),6.73-6.67(m,1H),4.00(s,3H)。
第三步
向化合物4c(1.2克,7.22毫摩尔)的醋酸(110毫升)溶液中,在氮气氛围下加入钯碳(120毫克,10%纯度)。反应混合物用氢气置换,混合物在氢气氛围(15psi)和25℃下搅拌32小时。将该混合物用硅藻土助滤,过滤。滤液再加入钯碳(100毫克,10%纯度),该混合物在氢气氛围(15psi)和30℃下搅拌16小时。将该混合物用硅藻土助滤,过滤,滤液浓缩得到化合物4d。
1H NMR(400MHz,CDCl
3)δ=6.71-6.62(m,1H),6.54-6.45(m,1H),4.74-4.62(m,2H),3.89-3.79(s,3H),3.33-3.22(m,2H)。
第四步
在-78℃下,向化合物4d(1.13克,6.72毫摩尔)的二氯甲烷(10毫升)溶液中加入三溴化硼(2.02克,8.06毫摩尔),该反应体系升温至20℃,并在20℃下搅拌2小时。在0℃下,向反应液中缓慢滴加饱和氯化铵水溶液(10毫升)淬灭反应,并向反应体系中加入水(10毫升),用乙酸乙酯(10毫升×3),合并有机相用食盐水(10毫升×3)洗涤。收集有机相用无水硫酸钠干燥,过滤浓缩得到化合物4e。
第五步
向化合物4e(1.94克,10.06毫摩尔)和3-氯甲基-1,2-二氟-4-甲氧基苯(1.55克,10.06毫摩尔)的甲苯 (10毫升)溶液中,加入四丁基溴化铵(324.17毫克,1.01毫摩尔)和氢氧化钠(804.42毫克,20.11毫摩尔)的水溶液(2毫升)。该混合物在50℃下搅拌12小时。向该反应体系中加入10毫升的水,用乙酸乙酯(20毫升×3)萃取,合并有机相用水(10毫升×3)洗涤,食盐水(10毫升×3)洗涤。收集有机相用无水硫酸钠干燥,过滤浓缩,经柱层析分离(硅胶,石油醚:乙酸乙酯=1:0-80:1)得到化合物4f。
1H NMR(400MHz,CDCl
3)δ=7.14-7.09(m,1H),6.81–6.78(m,1H),6.62–6.61(m,1H),6.50–6.46(m,1H),5.15–5.14(d,J=16.0Hz,2H),4.69–4.64(m,2H),3.83(s,3H),3.29–3.24(m,2H)。
第六步
在80℃下,向化合物4f(1.31克,4.22毫摩尔)的醋酸(1毫升)溶液中,逐滴加入硝酸(532.08毫克,60%纯度,5.07毫摩尔),该混合物在80℃下搅拌2小时。将该反应液倒入50毫升水中,有固体析出,过滤浓缩,再用10毫升混合溶剂(石油醚:乙酸乙酯=10:1)在20℃下打浆30分钟得到化合物4g。
1H NMR(400MHz,CDCl
3)δ=7.85-7.79(d,J=6.4Hz,1H),7.19-7.10(m,1H),6.66-6.60(m,1H),5.25(s,2H),4.89-4.77(m,2H),3.88(s,3H),3.41-3.32(m,2H)。
第七步
在氮气氛围下,向化合物4g(1.2克,3.38毫摩尔)的乙酸乙酯(5毫升)的溶液中加入钯碳(120毫克,10%纯度),氢气置换后,该混合物在氢气氛围(15psi)和25℃下搅拌16小时。将该反应液用硅藻土助滤,过滤,滤液浓缩得到化合物4h。
1H NMR(400MHz,CDCl
3)δ=7.14-7.05(m,1H),6.83-6.78(m,1H),6.60-6.55(m,1H),5.13-5.12(d,J=1.6Hz,2H),4.67-4.58(m,2H),3.82(s,3H),3.29-3.19(m,2H);MS-ESI计算值[M+H]
+:326.1,实测值326.1。
第八步
向化合物4h(100毫克,307.43微摩尔)的四氢呋喃(3毫升)溶液中,加入化合物1f(103毫克,307.43微摩尔)和三乙胺(31.11毫克,307.43微摩尔),该混合物在70℃下搅拌10小时。将该反应液倒入10毫升水中,用乙酸乙酯(30毫升×5)萃取,合并有机相用水(10毫升×3)洗涤,并用无水硫酸钠干燥,过滤,浓缩,粗品经制备色谱纯化(硅胶,石油醚:乙酸乙酯=3:1)得到化合物4i。
1H NMR(400MHz,CDCl
3)δ=8.82(s,1H),7.96(s,1H),7.32-7.28(m,1H),7.14-7.07(m,1H),6.60-6.54(m,1H),6.27(br s,1H),5.19-5.18(d,J=1.6Hz,2H),4.74-4.64(m,2H),3.91(s,3H),3.86(s,3H),3.82(s,3H),3.33-3.25(m,2H);MS-ESI计算值[M+H]
+:567.1,实测值567.1。
第九步
向化合物4i(102毫克,180.05微摩尔)的四氢呋喃(2毫升)和甲醇(1毫升)的溶液中加入一水合氢氧化锂(22.66毫克,540.16微摩尔)的水溶液(1毫升),该混合物在26℃下搅拌1小时。向该反应液中加 入1毫升的水,用1摩尔/升盐酸调节pH至5左右,然后用乙酸乙酯(10毫升×3)萃取,合并有机相用食盐水(10毫升×2)洗涤,收集有机相用无水硫酸钠干燥,过滤,浓缩,粗品经高效液相色谱制备分离(色谱柱:Phenomenex luna C18 150*25mm*10μm;流动相:[水(0.05%盐酸)-乙腈];乙腈%:42%-72%)得到化合物4。
1H NMR(400MHz,DMSO-d
6)δ=11.99(br s,1H),7.54-7.41(m,1H),7.36(s,1H),7.13-7.12(d,J=6.0Hz,1H),6.94-6.84(m,1H),5.00(s,2H),4.73-4.64(m,2H),3.81(s,3H),3.31-3.30(m,2H);MS-ESI计算值[M+H]
+:521.1,实测值521.0。
实施例5
第一步
向化合物5a(5-氟-2-甲氧基苯酚,3克,21.11毫摩尔)的N,N-二甲基甲酰胺(20毫升)溶液中加入碳酸铯(13.75克,42.22毫摩尔),该反应体系在70℃下搅拌1小时。然后向反应液中加入1,2-二溴乙烷(39.65克,211.08毫摩尔),该反应体系在70℃下搅拌18小时。将该反应体系倒入水(30毫升)中,用乙酸乙酯(50毫升×5)萃取,合并有机相用水(10毫升×5)洗涤。收集有机相用无水硫酸钠干燥,过滤浓缩,粗品经柱层析纯化(硅胶,石油醚:乙酸乙酯=1:0-200:1)得到化合物5b。
1H NMR(400MHz,CDCl
3)δ=6.86-6.80(m,1H),6.72-6.61(m,2H),4.32(t,J=6.6Hz,2H),3.86(s,3H),3.67(t,J=6.6Hz,2H)。
第二步
向化合物5b(2克,8.03毫摩尔)的二甲亚砜(20毫升)溶液中,加入叔丁醇钾(1.80克,16.06毫摩 尔)。该混合物在25℃下搅拌0.5小时。将该反应体系倒入20毫升水中,用二氯甲烷(50毫升×5)萃取,合并有机相用水(10毫升×5)洗涤,饱和食盐水洗涤1次。收集有机相用无水硫酸钠干燥,过滤浓缩得到化合物5c。
第三步
在0℃下,向化合物5c(900毫克,5.35毫摩尔)的二氯甲烷(10毫升)溶液中加入二碘甲烷(151.60克,192.67毫摩尔)。然后在0℃下,将二乙基锌(96.33毫升,1M)逐滴加入到该反应体系中。该混合物缓慢升温至25℃并在25℃下搅拌12小时。在0℃下,向该反应体系中加入3毫升饱和氯化铵水溶液和20毫升乙酸乙酯中,然后将该混合液倒入10毫升水中,分液,水相再用乙酸乙酯(10毫升×5)萃取,合并有机相后用水(10毫升×5)洗涤,食盐水洗涤1次。收集有机相用无水硫酸钠干燥,过滤浓缩,粗品经柱层析纯化(硅胶,石油醚:乙酸乙酯=1:0-100:1)得到化合物5d。
1H NMR(400MHz,CDCl
3)δ=7.03(dd,J=3.2,10.0Hz,1H),6.78(dd,J=5.2,8.8Hz,1H),6.62(m,1H),3.83(s,3H),3.76-3.70(m,1H),0.89-0.85(m,2H),0.85-0.78(m,2H)。
第四步
在-70℃下,向化合物5d(856毫克,4.70毫摩尔)的二氯甲烷(3毫升)溶液中加入三溴化硼(1.29克,5.17毫摩尔)的二氯甲烷(0.5毫升)溶液,该反应体系升温至0℃并在0℃下搅拌1小时。向反应液中缓慢滴加甲醇(2毫升)和水(10毫升),用二氯甲烷(30毫升×3)萃取,合并有机相用水(10毫升×3)洗涤,食盐水洗涤1次,收集有机相用无水硫酸钠干燥,过滤浓缩得到化合物5e。
1H NMR(400MHz,CDCl
3)δ=6.96(dd,J=3.2,10Hz,1H),6.83(dd,J=5.2,8.8Hz,1H),6.59(m,1H),5.28(br s,1H),3.87-3.72(m,1H),0.89-0.81(m,4H)。
第五步
向化合物5e(200毫克,1.19毫摩尔)和2-氯甲基-3,4-二氟-1-甲氧基苯(343.57毫克,1.78毫摩尔)的甲苯(5毫升)溶液中,加入四丁基溴化铵(38.34毫克,118.93微摩尔)。然后将氢氧化钠(95.14毫克,2.38毫摩尔)的水(1毫升)溶液加入到反应体系中。该混合物在50℃下搅拌12小时。将该反应体系倒入10毫升水中,用乙酸乙酯(20毫升×3)萃取,合并有机相用水(10毫升×3)洗涤,食盐水(10毫升×3)洗涤。收集有机相用无水硫酸钠干燥,过滤浓缩,粗品经柱层析纯化(硅胶,石油醚:乙酸乙酯=1:0-80:1)得到化合物5f。
1H NMR(400MHz,CDCl
3)δ=7.10(q,J=9.2Hz,1H),6.97(dd,J=3.2,10.4Hz,1H),6.92(dd,J=5.6,8.8Hz,1H),6.61-6.57(m,1H),6.56(td,J=1.6,3.0Hz,1H),5.09(d,J=2.0Hz,2H),3.80(s,3H),3.75-3.68(m,1H),0.81-0.76(m,4H)。
第六步
在80℃下,向化合物5f(281毫克,866.50微摩尔)的醋酸(10毫升)溶液中,加入硝酸(136.50毫克,97.50微升,60%纯度),该混合物在80℃下搅拌2小时。将该反应液倒入10毫升水,有固体析出。过滤,干燥滤饼得到化合物5g。
1H NMR(400MHz,CDCl
3)δ=7.86(d,J=7.6Hz,1H),7.18-7.07(m,2H),6.65-6.59(m,1H),5.22(d,J=1.6Hz,2H),3.88(s,3H),3.84-3.77(m,1H),0.95-0.88(m,2H),0.88(s,2H)。
第七步
向化合物5g(207毫克,560.53微摩尔)的乙醇(5毫升)和水(0.5毫升)溶液中,加入铁粉(156.53毫克,2.80毫摩尔)和氯化铵(17.99毫克,336.32微摩尔)。该混合物在85℃下搅拌1小时。将该反应液用硅藻土助滤过滤,滤饼用二氯甲烷(10毫升×5)洗涤,然后向滤液中加入水(10毫升),用二氯甲烷(10毫升×3)萃取,合并有机相,用水(10毫升×2)洗涤,无水硫酸钠干燥,过滤浓缩,粗品经柱层析纯化(硅胶,石油醚:乙酸乙酯=1:0-10:1)得到化合物5h。
1H NMR(400MHz,CDCl
3)δ=7.10(q,J=9.6Hz,1H),6.92(d,J=12.0Hz,1H),6.62-6.56(m,1H),6.52(d,J=8.8Hz,1H),5.06(s,2H),3.82(s,3H),3.69(tt,J=3.2,6.0Hz,1H),3.42(br s,2H),0.80-0.72(m,2H),0.72-0.64(m,2H);MS-ESI计算值[M+H]
+:340.1,实测值340.1。
第八步
向化合物5h(220毫克,583.54微摩尔)的四氢呋喃(5毫升)溶液中,加入化合物1f(195.68毫克,583.54微摩尔)和三乙胺(59.05毫克,583.54微摩尔)。该混合物在70℃下搅拌10小时。将该反应液中倒入30毫升水中,用乙酸乙酯(50毫升×5)萃取,合并有机相用水(20毫升×5),饱和食盐水(20毫升)洗涤,并用无水硫酸钠干燥,过滤,浓缩,粗品经柱层析纯化(硅胶,石油醚:乙酸乙酯=100:1-5:1)得到化合物5i。
1H NMR(400MHz,CDCl
3)δ=8.79(s,1H),7.96(s,1H),7.58(d,J=7.6Hz,1H),7.14-7.06(m,1H),7.04(d,J=7.6Hz,1H),6.60-6.54(m,1H),6.43(s,1H),5.15(d,J=1.6Hz,2H),3.91(s,3H),3.86(s,3H),3.81(s,3H),3.73(m,1H),0.91-0.85(m,2H),0.78-0.74(m,2H);MS-ESI计算值[M+H]
+:581.1,实测值581.1。
第九步
向化合物5i(324毫克,533.16微摩尔)的四氢呋喃(1毫升)和甲醇(1毫升)的溶液中加入一水合氢氧化锂(134.23毫克,3.20毫摩尔)的水溶液(0.5毫升),该混合物在28℃下搅拌2小时。向该反应液中加入1摩尔/升稀盐酸调节pH至6左右,析出固体,过滤,干燥滤饼得到化合物5。
1H NMR(400MHz,DMSO-d
6)δ=14.52(br s,1H),12.01(br s,1H),7.50-7.41(m,1H),7.39(s,1H),7.33(d,J =11.2Hz,1H),7.26(m,1H),6.93-6.86(m,1H),4.95(s,2H),3.91(m,1H),3.78(s,3H),0.87-0.77(m,2H),0.73-0.65(m,2H);MS-ESI计算值[M+H]
+:535.1,实测值535.0。
实施例6
第一步
将化合物6a(2-溴-4-氟-5-硝基苯酚,2克,8.47毫摩尔)溶于15毫升的N-甲基吡咯烷酮中,冷却到0℃,加入叔丁醇钾(1.14克,10.17毫摩尔),然后在0℃下搅拌30分钟,再将化合物2-氯甲基-3,4-二氟-1-甲氧基苯(2.77克,14.41毫摩尔)滴加到反应液中,在25℃下搅拌3小时。将反应液倒入100毫升的水中,并用乙酸乙酯萃取三次,每次30毫升,合并有机相浓缩,粗品经柱层析(硅胶,100-200目,石油醚:乙酸乙酯=1/0-10/1)纯化得化合物6b。
第二步
将化合物6b(300毫克,765.06微摩尔),环丙基硼酸(131.43毫克,1.53毫摩尔),醋酸钯(17.18毫克,76.51微摩尔),三(环己基)膦(42.91毫克,153.01微摩尔),磷酸钾(487.19毫克,2.30毫摩尔)溶于10毫升的甲苯和1毫升的水中,并用氮气置换三次,然后加热到100℃,在100℃下搅拌12小时。将反应液过滤,浓缩,粗品经柱层析(硅胶,100-200目,石油醚:乙酸乙酯=1/0-10/1)纯化得化合物6c。
第三步
将化合物6c(200毫克,566.10微摩尔)溶于6毫升的乙醇和0.6毫升的水中,加入铁粉(158.08毫克,2.83毫摩尔)和氯化铵(18.17毫克,339.66微摩尔),然后将反应液加热到85℃,在85℃下搅拌2小时。将反应液过滤,浓缩,粗品用20毫升的乙酸乙酯溶解,并用20毫升的水洗涤一次,再用10毫升的饱和食盐水洗涤一次,无水硫酸钠干燥,过滤,浓缩得化合物6d。
第四步
将化合物6d(140毫克,433.03微摩尔)溶于4毫升的四氢呋喃中,加入化合物1f(145.21毫克,433.02微摩尔)和三乙胺(43.82毫克,433.02微摩尔),然后加热到70℃,在70℃下搅拌12小时。将反应液浓缩,粗品经柱层析(硅胶,100-200目,石油醚:乙酸乙酯=1/0-10/1)纯化得化合物6e。
MS-ESI计算值[M+Na]
+:587.1,实测值587.1。
第五步
将化合物6e(120毫克,212.57微摩尔)溶于6毫升的四氢呋喃和1毫升的甲醇中,然后将一水合氢氧化锂(53.52毫克,1.28毫摩尔)溶于1毫升的水中,滴加到反应液中,在25℃下搅拌1小时。用1摩尔/升的稀盐酸将反应液调到pH至2-3,再用10毫升的水稀释,乙酸乙酯萃取3次,每次10毫升,合并有机相,10毫升的饱和食盐水洗涤1次,再用无水硫酸钠干燥,过滤,浓缩得化合物6。
1H NMR(400MHz,DMSO-d
6)δ=7.47(q,J=9.6Hz,1H),7.40-7.38(m,1H),7.39(s,1H),7.31(d,J=6.4Hz,1H),6.94-6.89(m,1H),6.86(d,J=11.2Hz,1H),5.03(s,2H),3.82(s,3H),2.11-2.03(m,1H),0.97-0.87(m,2H),0.73-0.68(m,2H);MS-ESI计算值[M+H]
+:519.1,实测值=519.0。
实施例7
第一步
在0-5℃下,向化合物7a(丙酮酸甲酯,21克,205.70毫摩尔)和氰基乙酸乙酯(23.27克,205.70毫摩尔)的N,N-二甲基甲酰胺(200毫升)溶液中加入硫粉(7.92克,246.84毫摩尔),滴加三乙胺(35.39克,349.70毫摩尔),混合物在50℃下搅拌2小时。反应液加水(500毫升),用乙酸乙酯萃取两次,每次100毫升,合并的有机相用水洗涤两次,每次200毫升,饱和食盐水(200毫升)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干,加入乙酸乙酯(5毫升),石油醚(50毫升),30℃下搅拌30分钟,过滤,滤饼减压干燥得到化合物7b。
第二步
在0-5℃下,向化合物7b(28克,122.14毫摩尔)的乙腈(300毫升)溶液中加入溴化亚铜(26.28克,183.20毫摩尔),亚硝酸叔丁酯(15.11克,146.56毫摩尔),反应混合物在25℃下搅拌12小时。向反应液加入水(100毫升),用乙酸乙酯萃取两次,每次100毫升,合并的有机相用饱和食盐水(100毫升)洗涤,无水硫酸钠干燥,过滤,滤液浓缩干,经硅胶柱层析(石油醚:乙酸乙酯=1:0到20:1)纯化得到化合物7c。
第三步
在-20℃下,向化合物7c(4.5克,15.35毫摩尔)的二氯甲烷(15毫升)溶液中,缓慢滴加三溴化硼(4.62克,18.42毫摩尔),反应液在25℃氮气保护下搅拌12小时。反应液过滤,滤饼用二氯甲烷洗涤两次,每次10毫升,滤饼丢弃。滤液加入水(10毫升)稀释,用1.0摩尔/升的氢氧化钠调节pH到10-11,二氯甲烷相丢弃。水相加入二氯甲烷(10毫升),用1.0摩尔/升的盐酸调节pH到3-4,二氯甲烷相用无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物7d。
第四步
向化合物7d(300毫克,1.07毫摩尔)的叔丁醇(2毫升)中,加入叠氮磷酸二苯酯(354.96毫克,1.29毫摩尔),三乙胺(163.15毫克,1.61毫摩尔)。反应物在85℃氮气保护下搅拌2小时。反应液加入水(10毫升),用乙酸乙酯萃取两次,每次10毫升,合并有机层,用饱和氯化钠水溶液(10毫升)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干,经薄层色谱法制备硅胶板(石油醚:乙酸乙酯=20:1)纯化得到化合物7e。
LC-MS:m/z=249.9[M+H-100]
+。
第五步
向化合物7e(110毫克,314.08微摩尔)和二乙氧基甲基膦(85.51毫克,628.16微摩尔)的N,N-二甲基甲酰胺(3毫升)溶液,加入磷酸钾(200.01毫克,942.24微摩尔),二苯基膦-9,9-二甲基氧杂氧杂蒽杂蒽(36.35毫克,62.82微摩尔),醋酸钯(7.05毫克,31.41微摩尔)。反应液在100℃氮气保护下搅拌12小时。向反应液中加入水(20毫升),用乙酸乙酯萃取两次,每次10毫升,合并有机相,用饱和食盐水(20毫升)洗涤,无水硫酸钠干燥,过滤,滤液浓缩干,经制备色谱板(石油醚:乙酸乙酯=1:2)纯化得到化合物7f。
1H NMR(400MHz,CDCl
3)δ=9.13(br s,1H),8.04(br s,1H),4.46(dq,J=2.0,7.2Hz,2H),4.21-4.11(m,1H),4.00-3.93(m,1H),1.88(d,J=16.0Hz,3H),1.52(s,9H),1.47(t,J=7.2Hz,3H),1.32(t,J=7.2Hz,3H)。
第六步
向化合物7f(20毫克,53.00微摩尔)的二氯甲烷(0.5毫升)溶液中,加入三氟乙酸(770.00毫克,6.75毫摩尔),反应液在25℃下搅拌1小时。反应液减压浓缩干得到化合物7g(三氟乙酸盐)。
LC-MS:m/z=278.1[M+H]
+。
第七步
向化合物7g(15毫克,38.33微摩尔,三氟乙酸盐)的四氢呋喃(0.5毫升)和水(0.5毫升)溶液中,加入碳酸钾(7.95毫克,57.50微摩尔),在5-10℃滴加氯甲酸苯酯(12.00毫克,76.67微摩尔),反应在5-10℃下搅拌1小时。液质联用色谱监测反应完全后,反应液加水(10毫升),用乙酸乙酯萃取两次,每次10毫升,合并的有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干得到7h。
LC-MS:m/z=398.1[M+H]
+。
第八步
在-70--65℃,向化合物7k(3,4-二氟苯甲醚,10克,69.39毫摩尔)的四氢呋喃(100毫升)溶液中加入2.0摩尔/升的二异丙基胺基锂(41.63毫升),在-70--65℃搅拌0.5小时,然后滴加N,N-二甲基甲酰胺(6.09克,83.26毫摩尔)的四氢呋喃(5毫升)溶液。混合物在-70--65℃搅拌1小时。在-70--65℃,加入醋酸(10毫升)和水(100毫升)的混合物,用乙酸乙酯萃取两次,每次100毫升,合并的有机相用100毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物7l。
第九步
在10-15℃,向化合物7l(12克,69.72毫摩尔)的甲苯(72毫升)溶液中,加入硼氢化钠(5.27克,139.43毫摩尔)的0.1摩尔/升的氢氧化钠(15毫升)溶液。反应液15℃搅拌4小时。加入100毫升水,用乙酸乙酯萃取两次,每次100毫升,合并的有机相用100毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物7m。
1H NMR(400MHz,CDCl
3)δ=7.07(q,J=9.1Hz,1H),6.63-6.54(m,1H),4.77(dd,J=1.5,6.4Hz,2H),3.88(s,3H)。
第十步
向化合物7m(12克,68.91毫摩尔)的甲苯(120毫升)中,加入氯化亚砜(12.30克,103.36毫摩尔),反应物在25℃氮气保护下搅拌2小时。反应液浓缩干,加入50毫升水,用饱和碳酸氢钠调节pH到7-8,用乙酸乙酯萃取两次,每次50毫升,合并有机层,50毫升饱和氯化钠水溶液洗一次,无水硫酸钠干燥,过滤,滤液减压浓缩干得到化合物7n。
第十一步
向化合物7n(1克,5.19毫摩尔)和4-氟-2-甲氧基苯酚(737.98毫克,5.19毫摩尔)的甲苯(40毫升)中,加四丁基溴化铵(167.38毫克,519.24微摩尔),氢氧化钠(415.36毫克,10.38毫摩尔)的水(2毫升)溶液,反应液在50℃下搅拌12小时。反应液加入10毫升水,用乙酸乙酯萃取两次,每次10毫升,合并有机相,用10毫升饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液浓缩干,得到化合物7p。
第十二步
向化合物7p(1.7克,5.70毫摩尔)的醋酸(12毫升)溶液中,滴加硝酸(990毫克,9.43毫摩尔,纯度60%),反应在60℃下搅拌0.5小时。加50毫升水,固体析出,过滤,滤饼减压干燥得到7q。
LC-MS:m/z=344.1[M+H]
+。
第十三步
向化合物7q(1.8克,5.24毫摩尔)的乙酸乙酯(150毫升)溶液中,加入湿钯碳(180毫克,10%纯度,50%水),反应在20℃氢气15psi下搅拌12小时。反应液过滤,滤液减压浓缩干,加入乙酸乙酯(5毫升),石油醚(50毫升),20℃打浆30分钟,过滤,减压干燥得到7j。
LC-MS:m/z=314.1[M+H]
+。
第十四步
向化合物7h(18毫克,45.30微摩尔)和化合物7j(14.19毫克,45.30微摩尔)的四氢呋喃(2毫升)溶液中,加入三乙胺(4.58毫克,45.30微摩尔),反应在33℃下搅拌120小时。反应液减压浓缩干,经制备色谱板(石油醚:乙酸乙酯=1:2)纯化得到7i。
LC-MS:m/z=617.1[M+H]
+。
第十五步
向化合物7i(7毫克,11.35微摩尔)的四氢呋喃(0.5毫升),甲醇(0.5毫升)和水(0.5毫升)溶液中,加入一水和氢氧化锂(2.38毫克,56.77微摩尔),反应在20℃下搅拌2小时。反应液用1摩尔每升的盐酸调节pH到3-4,固体析出,过滤,水洗涤两次,每次2毫升,滤饼浓缩干得到化合物7。
LC-MS:m/z=543.1[M+H]
+;
1H NMR(400MHz,CD
3OD)δ=7.27-7.19(m,1H),7.14(s,1H),7.05(br d,J=7.2Hz,1H),6.95(d,J=11.2Hz,1H),6.78(br d,J=9.4Hz,1H),5.10(s,2H),3.85(s,3H),3.80(s,3H),1.75(br d,J=15.2Hz,3H)。
实施例8
第一步
向化合物8a(5,6-二氟水杨醛,3g,18.98mmol)的DMF(30mL)溶液中加入碳酸铯(12.36g,37.95mmol),该反应体系在70℃下搅拌1小时。然后向反应液中加入1,2-二溴乙烷(17.82g,94.88mmol),该反应体系在70℃下搅拌18小时。将该反应体系倒入水(30mL)中,用乙酸乙酯(50mL×5)萃取,合并有机相用水(20mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=100/1-20/1)得到化合物8b。
第二步
在0℃下,向化合物8b(1.68g,6.34mmol)的四氢呋喃(30mL)和甲醇(6mL)溶液中,加入硼氢化钠(287.74mg,7.61mmol)。该混合物在25℃下搅拌0.5小时。在0℃下,向该反应液中加入10mL饱和氯化铵水溶液和20mL乙酸乙酯,该混合物在25℃下搅拌0.5小时。然后将该混合物倒入20mL水中,用乙酸乙酯(50mL×5)萃取,合并有机相依次用水(20mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩得到化合物8c。
1H NMR(400MHz,CDCl
3)δ=7.06(q,J=9.0Hz,1H),6.64-6.51(m,1H),4.80(br d,J=5.0Hz,2H),4.39-4.32(m,2H),3.74-3.69(m,2H),2.60(br t,J=6.8Hz,1H)。
第三步
在0℃下,向化合物8c(1.83g,16.85mmol)的二氯甲烷(5mL)溶液中,逐滴加入2,6-二甲基吡啶(1.10g,1.5eq)和三异丙基硅基(三氟甲基硫酸)酯(2.52g,1.2eq)。该混合物升温至25℃并在25℃下搅拌12小时。在0℃下,向该反应液中加入1mL饱和氯化铵水溶液和10mL乙酸乙酯,该混合物在25℃下搅拌0.5小时。然后将该混合物倒入10mL水中,用乙酸乙酯(50mL×5)萃取,合并有机相用水(10mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=1/0-50/1)得到化合物8d。
1H NMR(400MHz,CDCl
3)δ=7.04(q,J=9.2Hz,1H),6.62-6.54(m,1H),4.87(d,J=2.0Hz,2H),4.29(t,J=6.4Hz,2H),3.63(t,J=6.4Hz,2H),1.20-1.13(m,3H),1.12-1.08(m,18H)。
第四步
在0℃下,向化合物8d(2.97g,7.01mmol)的四氢呋喃(3mL)溶液中,加入叔丁醇钾(1.57g,14.03mmol)。该混合物在60℃下搅拌24小时。将该反应体系倒入10mL水中,用乙酸乙酯(10mL×5)萃取,合并有机相用水(10mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=1/0)得到化合物8e。
第五步
在0℃下,向化合物8e(1.8g,5.26mmol)的二氯甲烷(10mL)溶液中加入氯碘甲烷(33.37g,189.20mmol)。然后在0℃下,将二乙基锌(94.60mL,1M,94.60mmol)逐滴加入到该反应体系中。该混合物缓慢升温至25℃并在25℃下搅拌12小时。在0℃下,向该反应体系中加入1mL饱和氯化铵水溶液和10mL乙酸乙酯中,然后将该混合液倒入10mL水中,水相用乙酸乙酯(10mL×5)萃取,合并有机相用水(10mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=1/0)得到化合物8f。
第六步
向化合物8f(669mg,1.88mmol)的四氢呋喃(3mL)溶液中,加入TBAF(2.25mL,1M,2.25mmol),该混合物在27℃下搅拌1.3小时。向该反应液中逐滴加入10mL饱和碳酸氢钠水溶液淬灭反应。然后将该反应液倒入10mL水中,用乙酸乙酯(10mL×5)萃取,合并有机相用饱和碳酸氢钠水溶液(10mL×5),食盐水洗涤,并用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=1/0-20/1)得到化合物8g。
1H NMR(400MHz,CDCl
3)δ=7.11-7.03(m,1H),6.99-6.93(m,1H),4.75-4.70(m,2H),3.77(td,J=2.8,6.0Hz,1H),0.85-0.79(m,4H)。
第七步
在氮气氛围下,向化合物8g(518mg,2.59mmol)的甲苯(3mL)的溶液中加入氯化亚砜(307.85mg,2.59mmol),该混合物在28℃下搅拌2小时。向该反应体系中加入10mL水,用乙酸乙酯(20mL×3)萃取,合并有机相用水(10mL×3),食盐水(10mL×3)洗涤,收集有机相用无水硫酸钠干燥,过滤,浓缩得到粗品化合物8h。
1H NMR(400MHz,CDCl
3)δ=7.14-7.08(m,1H),6.99-6.94(m,1H),4.63(d,J=1.6Hz,2H),3.83-3.77(m,1H),0.83(d,J=4.4Hz,4H)。
第八步
向化合物8i(137.30mg,966.03μmmol)和化合物8h(528mg,粗品)的甲苯(5mL)溶液中,加入四丁基溴化铵(38.93mg,120.75μmmol)。然后将氢氧化钠(96.60mg,2.42mmol)的水(1mL)溶液加入到反应体系中。该混合物在50℃下搅拌12小时。将该反应体系倒入10mL水中,用乙酸乙酯(10mL×5)萃取,合并有机相用水(10mL×5),食盐水洗涤。收集有机相用无水硫酸钠干燥,过滤,滤液浓缩后经柱层析纯化(硅胶,石油醚/乙酸乙酯=1/0-100/1)得到化合物8j。
1H NMR(400MHz,CDCl
3)δ=7.11(q,J=9.2Hz,1H),6.97-6.91(m,1H),6.85-6.81(m,1H),6.63(dd,J=2.8,9.8Hz,2H),5.08(d,J=1.8Hz,2H),3.82(s,3H),3.75-3.67(m,1H),0.80-0.74(m,2H),0.73-0.67(m,2H)。
第九步
在0℃下,向化合物8j(90mg,277.3μmmol)的二氯甲烷(1mL)溶液中,加入浓硝酸(53.53mg,98%纯度,832.58μmmol)的二氯甲烷(0.5mL)溶液,该混合物在0℃下搅拌3小时。在0℃下,向该反应体系中再次加入浓硝酸(71.38mg,98%纯度,1.11mmol),该混合物在0℃下搅拌0.5小时。向该反应液中加入饱和碳酸氢钠水溶液调节pH至7,然后加入10mL水,用二氯甲烷(10mL×3)萃取。合并有机相用水(10mL×2)洗涤,饱和食盐水(10mL×2)洗涤。收集有机相用无水硫酸钠干燥,过滤浓缩得到化合物8k。
1H NMR(400MHz,CDCl
3)δ=7.79(d,J=7.4Hz,1H),7.20-7.09(m,1H),7.07-6.96(m,1H),6.71(d,J=12.4Hz,1H),5.23-5.17(m,2H),3.93(s,3H),3.86-3.72(m,1H),0.91-0.70(m,5H)。
第十步
向化合物8k(90mg,243.71μmmol)的乙醇(3mL)和水(0.3mL)溶液中,加入铁粉(68.06mg,1.22mmol)和氯化铵(7.82mg,146.23μmmol)。该混合物在85℃下搅拌1小时。将该反应液用硅藻土过滤,滤饼用二氯甲烷(10mL×5)洗涤,然后向滤液中加入水(10mL),用二氯甲烷(10mL×3)萃取,合并有机相,用水(10mL×2),食盐水(10mL×2)洗涤,无水硫酸钠干燥,过滤浓缩得到化合物8l。
LC-MS:m/z=340.1[M+H]
+;
1H NMR(400MHz,CDCl
3)δ=7.11(q,J=9.3Hz,1H),7.04-6.90(m,1H),6.64(d,J=12.0Hz,1H),6.49(d,J=8.9Hz,1H),5.04(d,J=1.6Hz,2H),3.75(s,3H),3.74-3.70(m,1H),0.79-0.75(m,2H),0.75-0.69(m,2H)。
第十一步
向化合物8l(70mg,206.30μmmol)的四氢呋喃(5mL)溶液中,加入化合物1f(69.18mg,206.30μmmol)和三乙胺(20.88mg,206.30μmmol)。该混合物在70℃下搅拌10小时。将该反应液中倒入30mL水中,用乙酸乙酯(50mL×5)萃取,合并有机相用水(20mL×5),饱和食盐水洗涤,并用无水硫酸钠干燥,过滤,滤液浓缩后经薄层色谱法制备分离(硅胶,石油醚/乙酸乙酯=2/1)得到化合物8m。
LC-MS:m/z=581.2[M+H]
+。
第十二步
向化合物8m(55mg,94.74μmmol)的四氢呋喃(1mL)和甲醇(1mL)的溶液中加入一水合氢氧化锂(23.85mg,568.45μmmol)的水溶液(0.5mL),该混合物在28℃下搅拌2小时。向该反应液中加入盐酸调节pH至6左右。然后用乙酸乙酯(5mL×5)萃取,合并有机相用水(5mL×3),饱和食盐水洗涤,并用无水硫酸钠干燥,过滤,滤液浓缩后经薄层色谱法制备分离(硅胶,二氯甲烷/甲醇=20/1)得到化合物8。
LC-MS:m/z=535.1[M+H]
+;
1H NMR(400MHz,DMSO-d
6)δ=14.53(br s,1H),11.99(br s,1H),7.50~7.45(m,1H),7.37(s,1H),7.21-7.10(m,3H),4.92(s,2H),3.94-3.88(m,1H),3.81(s,3H),0.78-0.71(m,2H),0.66-0.59(m,2H)。
生物测试数据
实验例1 本发明化合物对人源促性腺素释放激素受体活性的测试
实验目的:应用FLIPR检测技术,在细胞水平上检测受试化合物对促性腺激素释放激素受体的抑制活性主要实验材料及来源:
Fluo-4 Direct
TM试剂盒——Invitrogen-F10471公司
384孔多聚赖氨酸包被细胞板——Greiner-781946公司
384孔化合物板——Greiner-781280公司
化合物制备ECHO(声波移液系统)——Labcyte公司
FLIPR(荧光成像读板仪)——Molecular Devices公司
实验方案:
取对数生长期的GnRH/HEK293(人胚胎肾细胞293)培养细胞,用DPBS(杜氏磷酸缓冲盐)缓冲液清洗,加入适量0.05%的EDTA(乙二胺四乙酸)-胰酶放置于37℃二氧化碳培养箱中消化,1~2分钟取出细胞加入培养基终止消化。反复吹打分散细胞后离心收取细胞,以每孔20,000个细胞,20μL的密度种入384孔多聚赖氨酸包被细胞板,5%CO
2,37℃培养箱孵育过夜。
第二天每孔加入20μL 2×Fluo-4Direct
TM缓冲液,5%CO
2,37℃培养箱孵育50分钟,室温放置细胞10min。将0.2mM Leuprolide acetate(醋酸亮瑞丙林)用ECHO做4倍10个点的梯度稀释,并转移900nL到化合物板。添加30μL FLIPR缓冲盐溶液至化合物板中,1000rpm离心1min。运行FLIPR仪器软件,按照设定程序,加入10μL实验用缓冲盐溶液,读取荧光信号。然后再加入10μL激动剂参考化合物,读取荧光信号,计算EC
80,准备6×EC
80浓度的激动剂。
将2mM受试化合物及合适浓度的参考化合物用ECHO做4倍10个点的梯度稀释,并转移900nL至化合物板。添加30μL FLIPR缓冲盐溶液至化合物板中,1000rpm离心1min。运行FLIPR仪器软件,按照设定程序,添加10μL受试及参考化合物到细胞板中,读取荧光信号。再添加10μL 6×EC
80浓度的激动剂到细胞板中,读取荧光信号。
计算化合物对促性腺激素释放激素受体的钙流抑制的IC
50,即在稳定表达GnRH受体的细胞内Ca
2+流动被抑制一半时的药物浓度,应用GraphPad Prism 5.0软件计算药物的IC
50。
实验结果:本发明中化合物对人源促性腺激素释放激素受体抑制活性通过以上试验方法进行测定,测得的IC
50见表1。
表1 本发明化合物对人源促性腺激素释放激素受体活性抑制结果
化合物编号 | IC 50(nM) |
化合物1 | 2.3 |
化合物2 | 40.1 |
化合物3 | 38.9 |
化合物4 | 14.8 |
化合物5 | 3.4 |
化合物6 | 13.9 |
化合物7 | 15.2 |
化合物8 | 7.8 |
结论:本发明化合物对人源促性腺激素释放激素受体具有显著的抑制作用。
实验例2 药代动力学评价
实验目的:研究本发明化合物在小鼠体内药代动力学性质
试验方案:
各受试化合物分别与DMAC混合,涡旋2分钟,再将受试化合物的DMAC溶液混合后涡旋2分钟,制备得到10mg/mL的澄清溶液。取0.0600mL的10mg/mL溶液加入0.300mL Solutol,涡旋2分钟,再加入2.400mL的生理盐水,涡旋2分钟得到0.2mg/mL的澄清溶液,用于PO组给药。取0.500mL的PO组给药溶液,涡旋2分钟,加入0.0500mL的DMAC,混合后涡旋2分钟,然后加入0.0500mL的solutol,涡旋2分钟,最后加入0.400mL的生理盐水,涡旋两分钟得到0.1mg/mL的澄清溶液,微孔滤膜过滤后得到注射组(IV)给药溶液。
将4只雄性CD-1小鼠分为2组。第1组动物单次静脉给药,剂量为0.5mg/kg,溶媒为10%DMAC/10%Solutol/80%生理盐水,给药体积为5mL/kg。第2组动物单次灌胃口服2mg/kg的受试化合物,口服溶媒为10%DMAC/10%Solutol/80%生理盐水,口服体积为10mL/kg。在给药后0.033(仅静脉注射)、0.083、0.25、0.5、1、2、4和12小时采集全血。全血在3200g,2-8℃离心10min后得到血浆,用LC/MS/MS法测定血浆中受试化合物的浓度,并用Phoenix WinNonlin软件计算药代参数。
实验结果:
测试结果见表2。各参数含义:IV:静脉注射;PO:口服;C
0:初始血药浓度;C
max:体循环中最大药物浓度;T
max:达到C
max所需的时间;T
1/2:半衰期;V
dss:表观分布容积;Cl:清除率;AUC
0-last:药时曲线下面积。
表2 化合物1在血浆中的药物代谢动力学(PK)测试结果
参数 | IV(0.5mg/kg) | PO(2mg/kg) |
C 0(nmol/L) | 17017 | -- |
C max(nmol/L) | -- | 22250 |
T max(h) | -- | 0.750 |
T 1/2(h) | 14.9 | 16.9 |
V dss(L/kg) | 0.185 | -- |
Cl(mL/min/kg) | 0.162 | -- |
AUC 0-last(h*nmol/L) | 89645 | 251921 |
生物利用度(%) | -- | 77.0 |
“--”是指未测试或未获得数据
结论:本发明化合物在血浆中的暴露量高,清除率低,半衰期长,口服生物利用度高,展现了优秀的药代动力学性质,是良好的开发口服给药的分子。
实验例3 本发明化合物在体内动物肿瘤模型上的抗肿瘤活性测试
实验目的:在人前列腺癌LNCaP clone FGC异种移植瘤模型上考察本发明化合物的抑瘤效果
实验方法:
在雄性CB17-SCID小鼠皮下接种LNCaP clone FGC人前列腺癌细胞株,接种后第17天(接种当天作为第0天)按照肿瘤体积和体重随机分为手术组与非手术组,并且对手术组(6只动物)进行去势手术,接种后第20天,对非手术组的动物按照肿瘤体积和体重随机分为非手术对照组和化合物组(每组6只动物),并且按照下列描述进行给药处理。
第1组(非手术对照组):接种第20天分组后当天下午开始给药,每天一次,按照0.1mL/10g体重的剂量灌胃给药溶媒(5%DMSO+40%PEG400+10%solutol+45%水)。
第2组(去势手术组):接种第20天分组后当天下午开始给药,每天一次,按照0.1mL/10g体重的剂量灌胃给药溶媒(5%DMSO+40%PEG400+10%solutol+45%水)。
第3组(化合物1):接种第20天分组后当天下午开始给药,每天一次,按照100mg/kg体重的剂量灌胃给药化合物1,溶媒为10%DMAC+10%solutol+80%生理盐水。
实验期间每周两次测量肿瘤体积并且称量小鼠体重,并计算肿瘤增殖率。
计算公式:肿瘤体积=长×宽
2/2,肿瘤增殖率=治疗组肿瘤体积/非手术对照组肿瘤体积×100%。组间用Student’s t-test进行统计学分析,p<0.05为有显著性差异。
实验结果:
在人前列腺癌LNCaP clone FGC异种移植瘤模型上,去势手术组在给药第21天的肿瘤增殖率为69.52%,化合物1在给药第21天的肿瘤增殖率为37.09%(与非手术对照组相比p<0.05)。具体结果见表3。
表3 本发明化合物在人前列腺癌LNCaP clone FGC异种移植瘤模型上的抑制结果
结论:本发明化合物具有显著的抗肿瘤效果。
Claims (19)
- 式(II)所示化合物或其药学上可接受的盐,其中,R 1选自C 3-6环烷基、-S(=O) m-C 1-3烷基、-S(=O) m-C 3-6环烷基和-O-C 3-6环烷基,所述C 3-6环烷基、-S(=O) m-C 1-3烷基、-S(=O) m-C 3-6环烷基和-O-C 3-6环烷基分别独立地任选被1、2或3个R a取代;R 2和R 3各自独立地选自H、F、Cl、Br、I和C 1-3烷基,所述C 1-3烷基任选被1、2或3个R b取代;各R 4分别独立地选自F、Cl、Br、I、C 1-3烷氧基、-O-C 3-6环烷基和C 3-6环烷基,所述C 1-3烷氧基、-O-C 3- 6环烷基和C 3-6环烷基分别独立地任选被1、2或3个R c取代;或者,R 1和R 2与它们连接的原子一起形成环B,其中环B选自5-6元杂环基,所述5-6元杂环基任选被1、2或3个F取代;R 8选自-C(=O)OR 6和-P(=O)(R 7)OR 6;R 6选自H和C 1-3烷基,所述C 1-3烷基任选被1、2或3个F取代;R 7选自C 1-3烷基,所述C 1-3烷基任选被1、2或3个F取代;n选自1、2、3和4;m选自0、1和2;各R a、R b和R c分别独立地选自H、F、Cl、Br和I。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 1选自环丙基、环丁基、-S(=O) m-C 1-3烷基和-O-环丙基,所述环丙基、环丁基、-S(=O) m-C 1-3烷基和-O-环丙基分别独立地任选被1、2或3个R a取代。
- 根据权利要求2所述化合物或其药学上可接受的盐,其中,R 1选自-S(=O) m-C 1-3烷基,所述-S(=O) m-C 1-3烷基任选被1、2或3个R a取代。
- 根据权利要求3或4所述化合物或其药学上可接受的盐,其中,R 1选自-SCH 3、-SCF 3、-SCF 3、-SCH 2CH 3、-SCH 2CF 3、-S(=O)CH 3和-S(=O) 2CH 3。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 2选自H、F、Cl和CH 3,所述CH 3任选被1、2或3个F取代。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 3选自H、F、Cl和CH 3,所述CH 3任选被1、2或3个F取代。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 2和R 3各自独立地选自H。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 4选自F、Cl、-OCH 3、-OCH 2CH 3、-O-环丙基、-O-环丁基、环丙基和环丁基,所述-OCH 3、-OCH 2CH 3、-O-环丙基、-O-环丁基、环丙基和环丁基分别独立地任选被1、2或3个F取代。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 8选自-C(=O)OH和-P(=O)(CH 3)OH。
- 根据权利要求1~18任意一项所述的化合物或其药学上可接受的盐在制备GnRH受体拮抗剂相关的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280016639.1A CN116940575A (zh) | 2021-02-23 | 2022-02-21 | 噻吩并嘧啶二酮类化合物及其应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110205200.0 | 2021-02-23 | ||
CN202110205200 | 2021-02-23 | ||
CN202210128005.7 | 2022-02-10 | ||
CN202210128005 | 2022-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022179469A1 true WO2022179469A1 (zh) | 2022-09-01 |
Family
ID=83047749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/077035 WO2022179469A1 (zh) | 2021-02-23 | 2022-02-21 | 噻吩并嘧啶二酮类化合物及其应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116940575A (zh) |
TW (1) | TWI796144B (zh) |
WO (1) | WO2022179469A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1939204A1 (en) * | 2005-10-19 | 2008-07-02 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
WO2021023877A2 (en) * | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2022
- 2022-02-21 WO PCT/CN2022/077035 patent/WO2022179469A1/zh active Application Filing
- 2022-02-21 CN CN202280016639.1A patent/CN116940575A/zh active Pending
- 2022-02-21 TW TW111106220A patent/TWI796144B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1939204A1 (en) * | 2005-10-19 | 2008-07-02 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
WO2021023877A2 (en) * | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
Also Published As
Publication number | Publication date |
---|---|
TW202233633A (zh) | 2022-09-01 |
TWI796144B (zh) | 2023-03-11 |
CN116940575A (zh) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021203768A1 (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
CN105153122A (zh) | [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用 | |
BR112021004269A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, relacionada à proteína crbn e método para tratamento da mesma | |
WO2022143940A1 (zh) | 一系列哌啶取代的苯酸类化合物及其应用 | |
TWI765451B (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
AU2022227642B2 (en) | Fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compound and use thereof | |
CN112745335A (zh) | 一种三并杂环化合物及其用途 | |
WO2018084321A1 (ja) | Egfr阻害及び腫瘍治療に有用な新規化合物 | |
WO2022057838A1 (zh) | 异色满类化合物 | |
CN107759600A (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
CN114736214B (zh) | 一种倍半萜衍生物、其药物组合物及其制备方法和用途 | |
TWI807697B (zh) | 呋喃稠環取代的戊二醯亞胺類化合物 | |
WO2022171143A1 (zh) | 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物 | |
WO2020063965A1 (zh) | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 | |
WO2022179469A1 (zh) | 噻吩并嘧啶二酮类化合物及其应用 | |
JP7296017B2 (ja) | ベンゾスルタムを含む化合物 | |
WO2022222911A1 (zh) | 嘧啶酮化合物及其用途 | |
WO2022161347A1 (zh) | 三并环类化合物及其应用 | |
KR20200065056A (ko) | 트립톨라이드 유도체 및 이의 제조방법과 응용 | |
AU2020214518B2 (en) | Fluorovinylbenzamide compound as PD-L1 immunomodulator | |
JP2022517396A (ja) | Egfr阻害剤の塩、結晶形及びその製造方法 | |
WO2023083200A1 (zh) | 吡唑并环化合物及其应用 | |
TWI808786B (zh) | 酮類衍生物 | |
WO2022171013A1 (zh) | 四氢喹唑啉类化合物 | |
AU2021348707B2 (en) | Crystal form of pyridinylphenyl compound and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22758833 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280016639.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.12.2023) |